

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

BLACK BORDERS

- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

C12N-015/09B; C12N-015/10B; C12N-015/13B; C12N-015/63B; C12P-021/02B;
C12P-021/08B DESIGNATED COUNTRIES: AM; AU; BB; BG; BR; CA; CN; CZ; EE;
FI; GE; HU; IS; JP; KP; KR; KZ; LK; LR; LT; LV; MD; NG; MN; MX; NO; NZ;
PL; RO; RU; SG; SI; SK; TJ; TM; TT; UA; UG; US; UZ; VN

DESIGNATED REGIONAL: KE; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FR; GB;
GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE;
SN; TD; TG

SECTION:

CA263003 Pharmaceuticals

CA203XXX Biochemical Genetics

CA215XXX Immunochemistry

IDENTIFIERS: antibody complement C5 cloning glomerulonephritis sequence

DESCRIPTORS:

Antibodies, monoclonal... Deoxyribonucleic acid sequences, complementary...

Hybridoma... Immunoglobulins, G... Kidney, disease, glomerulonephritis...

Molecular cloning... Packaging materials... Polymerase chain reaction...

Protein sequences...

anti-complement C5 antibodies for the treatment of glomerulonephritis
and other inflammatory diseases

Immune complexes...

deposition of; anti-complement C5 antibodies for the treatment of
glomerulonephritis and other inflammatory diseases

Proteins, metabolic disorders, proteinuria, biological studies...

inhibition of; anti-complement C5 antibodies for the treatment of
glomerulonephritis and other inflammatory diseases

Antigens...

KSSKC epitope, antibodies binding to; anti-complement C5 antibodies for
the treatment of glomerulonephritis and other inflammatory diseases

CAS REGISTRY NUMBERS:

172893-24-2P 173011-96-6P 173012-07-2 173012-10-7P 173012-12-9P

173012-14-1P 173012-17-4P 173012-19-6P 173012-21-0P 173012-23-2P

173012-25-4P 173012-27-6P 173012-29-8P amino acid sequence;

anti-complement C5 antibodies for the treatment of glomerulonephritis
and other inflammatory diseases

80295-53-0 antibodies to; anti-complement C5 antibodies for the treatment
of glomerulonephritis and other inflammatory diseases

172998-82-2P epitope KSSKC-contg. antigen; anti-complement C5 antibodies
for the treatment of glomerulonephritis and other inflammatory diseases

173012-09-4P 173012-11-8P 173012-13-0P 173012-15-2P 173012-16-3P

173012-18-5P 173012-20-9P 173012-22-1P 173012-24-3P 173012-26-5P

173012-28-7P 173012-30-1P 173146-43-5 173146-44-6 173146-45-7

nucleic acid sequence; anti-complement C5 antibodies for the treatment
of glomerulonephritis and other inflammatory diseases

173016-57-4 PCR primer UDEC395; anti-complement C5 antibodies for the
treatment of glomerulonephritis and other inflammatory diseases

173016-56-3 PCR primer UDEC690; anti-complement C5 antibodies for the
treatment of glomerulonephritis and other inflammatory diseases

? s (c5) and (complement) and (arthriti?) (20n) (treat? or therap? or reduc? or
suppress? or inhibit?)

>>>Operator "(5C)" in invalid position

? s (complement) and c5 and (arthriti?) (20n) (treat? or therap? or reduc? or
suppress? or inhibit?)

Processing

Processing

Processing

Processing

Processing

Processing

228115 COMPLEMENT

18672 C5

306814 ARTHRITI?

4725177 TREAT?

4444220 THERAP?

2671566 REDUC?

584234 SUPPRESS?

2988896 INHIBIT?

72923 ARTHRITI?(20N) (((TREAT? OR THERAP?) OR REDUC?) OR
SUPPRESS?) OR INHIBIT?)
S7 36 (COMPLEMENT) AND C5 AND (ARTHRITI?)(20N) (TREAT? OR
THERAP? OR REDUC? OR SUPPRESS? OR INHIBIT?)
? rd s7
...completed examining records
S8 26 RD S7 (unique items)
? t s8/3/all

8/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

10081205 BIOSIS NO.: 199598536123
Anti-C5 monoclonal antibody **therapy** prevents collagen-induced
arthritis and ameliorates established disease.
AUTHOR: Wang Yi(a); Rollins Scott(a); Madri Joe; Matis Louis(a)
AUTHOR ADDRESS: (a)Alexion Pharmaceutical Inc., 25 Science Park, New Haven,
CT 06511**USA
JOURNAL: Arthritis & Rheumatism 38 (9 SUPPL.):pS372 1995
CONFERENCE/MEETING: 59th National Scientific Meeting of the American
College of Rheumatology and the 30th National Scientific Meeting of the
Association of Rheumatology Health Professionals San Francisco,
California, USA October 21-26, 1995
ISSN: 0004-3591
RECORD TYPE: Citation
LANGUAGE: English

8/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

07659768 BIOSIS NO.: 000092017189
COMPLEMENT C4-DERIVED MONOCYTE-DIRECTED CHEMOTAXIS-INHIBITORY
FACTOR A MOLECULAR MECHANISM TO CAUSE POLYMORPHONUCLEAR
LEUKOCYTE-PREDOMINANT INFILTRATION IN RHEUMATOID **ARTHRITIS** SYNOVIAL
CAVITIES
AUTHOR: MATSUBARA S; YAMAMOTO T; TSURUTA T; TAKAGI K; KAMBARA T
AUTHOR ADDRESS: DEP. ALLERGY, INST. MED. IMMUNOLOGY, KUMAMOTO UNIV. MED.
SCH., 2-2-1 HONJO, KUMAMOTO 860, JPN.
JOURNAL: AM J PATHOL 138 (5). 1991. 1279-1291.
FULL JOURNAL NAME: American Journal of Pathology
CODEN: AJPAA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

8/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

07298749 BIOSIS NO.: 000090078636
EFFECT OF DIET **THERAPY** ON CLINICAL IMMUNOLOGICAL INDICES IN
RHEUMATOID **ARTHRITIS** PATIENTS
AUTHOR: SHARAFETDINOV KH KH; DENISOV L N; SAMSONOV M A; PROKROVSKAYA G R;
VOITKO N E
AUTHOR ADDRESS: CLIN. MED. NUTR., INST. NUTR., ACAD. MED. SCI. USSR,
MOSCOW, USSR.
JOURNAL: VOPR PITAN 0 (1). 1990. 18-22.
FULL JOURNAL NAME: Voprosy Pitaniya
CODEN: VPITA
RECORD TYPE: Abstract
LANGUAGE: RUSSIAN

8/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Bio Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

06865550 BIOSIS NO.: 000089015140
COMPLEMENT BIOSYNTHESIS IN HUMAN SYNOVIAL TISSUE
AUTHOR: MOFFAT G J; LAPPIN D; BIRNIE G D; WHALEY K
AUTHOR ADDRESS: DEP. PATHOL., WESTERN INFIRMARY, GLASGOW G11 6NT, SCOTLAND.
JOURNAL: CLIN EXP IMMUNOL 78 (1). 1989. 54-60.
FULL JOURNAL NAME: Clinical and Experimental Immunology
CODEN: CEXIA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

8/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

04179782 BIOSIS NO.: 000077005826
D PENICILLAMINE IN RHEUMATOID ARTHRITIS LABORATORY FINDINGS WITH PARTICULAR
REFERENCE TO **COMPLEMENT** AND IMMUNO GLOBULINS
AUTHOR: MBUYI-MUAMBA J M; DEQUEKER J; STEVENS E
AUTHOR ADDRESS: RHEUMATOL. UNIT, HOSP. STE BARBARA, UNIV. LEUVEN, BELG.
JOURNAL: ACTA CLIN BELG 37 (5). 1982. 299-306.
FULL JOURNAL NAME: Acta Clinica Belgica
CODEN: ACCBA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

8/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

03338795 BIOSIS NO.: 000072066899
SUPPRESSION OF IN-VITRO ANTIBODY RESPONSE OF HUMAN PERIPHERAL BLOOD
LYMPHOCYTES BY A HEAT LABILE FACTOR IN NORMAL HUMAN SERUM
AUTHOR: ALDO-BENSON M A; PETERSEN B H; BENSON M D
AUTHOR ADDRESS: DIV. RHEUMATOL., INDIANA UNIV. SCH. MED., 1100 WEST
MICHIGAN ST., INDIANAPOLIS, INDIANA 46223, USA.
JOURNAL: CLIN EXP IMMUNOL 44 (3). 1981. 638-645.
FULL JOURNAL NAME: Clinical and Experimental Immunology
CODEN: CEXIA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

8/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

03018548 BIOSIS NO.: 000070044166
A HYPO COMPLEMENTEMIC VASCULITIC URTICARIAL SYNDROME 4 NEW CASES AND
DEFINITION OF THE DISEASE
AUTHOR: ZEISS C R; BURCH F X; MARDER R J; FUREY N L; SCHMID F R; GEWURZ H
AUTHOR ADDRESS: SECT. ALLERGY-IMMUNOL., NORTHWEST. UNIV. MED. SCH., 303 E.
CHICAGO AVE., CHICAGO, ILL. 60611, USA.
JOURNAL: AM J MED 68 (6). 1980. 867-875.
FULL JOURNAL NAME: American Journal of Medicine
CODEN: AJMEA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

8/3/8 (Item 8 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)
(c) 1999 BIOSIS. All reserv.

01964883 BIOSIS NO.: 000062054995
HEREDITARY DEFICIENCY OF THE **COMPLEMENT** C-5 IN MAN PART 1 CLINICAL
IMMUNOCHEMICAL AND FAMILY STUDIES
AUTHOR: ROSENFELD S I; KELLY M E; LEDDY J P
JOURNAL: J CLIN INVEST 57 (6). 1976 1626-1634.
FULL JOURNAL NAME: Journal of Clinical Investigation
CODEN: JCINA
RECORD TYPE: Abstract

8/3/9 (Item 1 from file: 73)
DIALOG(R)File 73: EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

07540499 EMBASE No: 1999030991
Pseudoporphyria associated with Relafen therapy
Magro C.M.; Crowson A.N.
Dr. C.M. Magro, Ameripath Cutaneous Pathol Immunofl, 23250 Chagrin
Boulevard, Cleveland, OH 44122 United States
Journal of Cutaneous Pathology (J. CUTANEOUS PATHOL.) (Denmark) 1999,
26/1 (42-47)
CODEN: JCUPB ISSN: 0303-6987
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 34

8/3/10 (Item 2 from file: 73)
DIALOG(R)File 73: EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06705349 EMBASE No: 1996370298
Prognostic significance of **complement** alleles Bf and C4 in early
rheumatoid arthritis
Paimela L.; Leirisalo-Repo M.; Lokki M.-L.; Koskimies S.
Helsinki City Hospital, Talvelantie 6, FIN-00700 Helsinki Finland
Clinical Rheumatology (CLIN. RHEUMATOL.) (Belgium) 1996, 15/6
(594-598)
CODEN: CLRHD ISSN: 0770-3198
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

8/3/11 (Item 3 from file: 73)
DIALOG(R)File 73: EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06685625 EMBASE No: 1996350544
Anti-C5 monoclonal antibody: A novel anti-inflammatory agent
Expert Opinion on Therapeutic Patents (EXPERT OPIN. THER. PAT.) (United
Kingdom) 1996, 6/11 (1229-1230)
CODEN: EOTPE ISSN: 1354-3776
DOCUMENT TYPE: Journal; Short Survey
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

8/3/12 (Item 4 from file: 73)
DIALOG(R)File 73: EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

05158337 EMBASE No: 1992298570
Anticomplementary activity of boswellic acids - An inhibitor of
C3-convertase of the classical **complement** pathway

Kapil A.; Moza N.
Pharmacology Division Regional Research Laboratory, Jammu Road, Jammu
Tawi-180 001 India
International Journal of Immunopharmacology (INT. J. IMMUNOPHARMACOL.)
(United Kingdom) 1992, 14/7 (1139-1143)
CODEN: IJIMD ISSN: 0192-0561
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

8/3/13 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

02755139 EMBASE No: 1984074098
Diminished activity of a chemotactic inhibitor in synovial fluids from
patients with familial Mediterranean fever
Matzner Y.; Partridge R.E.H.; Levy M.; Babior B.M.
Department of Hematology, Hadassah Medical School, Jerusalem Israel
Blood (BLOOD) (United States) 1984, 63/3 (629-633)
CODEN: BLOOA
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

8/3/14 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

02613620 EMBASE No: 1984182578
Development and clinical application of electroimmunoassays for the
direct quantification of the **complement** C3 split products C3c and C3d
Brandslund I.; Teisner B.; Hyltoft Petersen P.; Svehag S.-E.
Institute of Medical Microbiology, Odense University, Odense Denmark
Scandinavian Journal of Clinical and Laboratory Investigation (SCAND. J.
CLIN. LAB. INVEST.) (Norway) 1984, 44/SUPPL. 168 (57-73)
CODEN: SJCLA
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

8/3/15 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

02590284 EMBASE No: 1984209242
Relation of clinical activity of rheumatoid arthritis to immune
complexes, **complement** components and anti-immunoglobulins
Takemura S.; Ueda M.; Tagami H.; et al.
Department of Medicine, Kyoto Prefectural University of Medicine,
Kamikyo-ku, Kyoto 602 Japan
Rheumatology International (RHEUMATOL. INT.) (Germany) 1984, 4/4
(159-163)
CODEN: RHIND
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

8/3/16 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

01652027 EMBASE No: 1980146513
A hypocomplementemic vasculitic urticarial syndrome. Report of four new
cases and definition of the disease
Zeiss C.R.; Burch F.X.; Marder R.J.; et al.

Sect. Allergy-Immunol., Dept. Med., Northwest. Univ. Med. Sch., Chicago,
Ill. 60611 United States
American Journal of Medicine (AM. J. MED.) (United States) 1980, 68/6
(867-875)
CODEN: AJMEA
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

8/3/17 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

00541981 EMBASE No: 1976097599
Plasma and cell derived inhibitors of human neutrophil chemotaxis
Goetzl E.J.
Dept. Med., Robert B. Brigham Hosp., Boston, Mass. 02120 United States
Annals of the New York Academy of Sciences (ANN. NEW YORK ACAD. SCI.)
1975, Vol. 256/- (210-221)
CODEN: ANYAA
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

8/3/18 (Item 10 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

00223302 EMBASE No: 1974213473
Arthritis, deformities, and runtting in C5 deficient mice injected
with human rheumatoid arthritis synovium
Crocker J.F.S.; Ghose T.; Rozee K.; et al.
Dept. Ped., Dalhousie Univ., Halifax Canada
Journal of Clinical Pathology (J. CLIN. PATHOL.) 1974, 27/2 (122-124)
CODEN: JCPAA
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

8/3/19 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

07134668 92382057
A case of C5 deficiency with polyarthritis]
Mimori M; Yamauchi I; Nishimura Y; Takada K; Inai S
Department of Laboratory Medicine, Iwaki Kyoritsu General Hospital.
Rinsho Byori (JAPAN) Jun 1992, 40 (6) p660-4, ISSN 0047-1860
Journal Code: KIV
Languages: JAPANESE Summary Languages: ENGLISH
Document type: JOURNAL ARTICLE English Abstract

8/3/20 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

06400955 90266554
[The effect of dietotherapy on the clinico-immunological indices of
rheumatoid arthritis patients]
Vliianie dietoterapii na kliniko-immunologicheskie pokazateli bol'nykh
revmatoidnym artritom.
Sharafetdinov KhKh; Denisov LN; Samsonov GR; Pokrovskaja GR; Voitko NE
Vopr Pitan (USSR) Jan-Feb 1990, (1) p18-22, ISSN 0042-8833
Journal Code: XK4
Languages: RUSSIAN Summary Languages: ENGLISH

8/3/21 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

05944698 89215526
Passive collagen arthritis induced by anticollagen IgG.
Kerwar SS; Oronsky AL
Department of Inflammation and Immunology, American Cyanamid Company,
Lederle Laboratories, Pearl River, New York 10965.
Int Rev Immunol (SWITZERLAND) Sep 1988, 4 (1) p17-23, ISSN 0883-0185
Journal Code: IRI
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

8/3/22 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

05881329 88272098
[A study on type II collagen induced arthritis in mice]
Fujita M
Section of Pathology, Institute of Immunological Science, Hokkaido
University, Sapporo, Japan.
Hokkaido Igaku Zasshi (JAPAN) May 1988, 63 (3) p415-24, ISSN
0367-6102 Journal Code: GA9
Languages: JAPANESE Summary Languages: ENGLISH
Document type: JOURNAL ARTICLE English Abstract

8/3/23 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

03192647 75133807
The pathogenesis of arthritis associated with acute hepatitis-B surface
antigen-positive hepatitis. **Complement** activation and
characterization of circulating immune complexes.
Wands JR; Mann E; Alpert E; Isselbacher KJ
J Clin Invest (UNITED STATES) May 1975, 55 (5) p930-6; ISSN 0021-9738
Journal Code: HS7
Languages: ENGLISH
Document type: JOURNAL ARTICLE

8/3/24 (Item 6 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

03118490 75212053
Acute anaphylaxis associated with serum **complement** depletion.
Tannenbaum H; Ruddy S; Schur PH
J Allergy Clin Immunol (UNITED STATES) Sep 1975, 56 (3) p226-34,
ISSN 0091-6749 Journal Code: H53
Languages: ENGLISH
Document type: JOURNAL ARTICLE

8/3/25 (Item 7 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

02314576 76075557

Arthritis associated with intestinal-bypass procedure for morbid obesity.
Complement activation and characterization of circulating
cryoproteins.

Wands JR; LaMont JT; Mann E; Isselbacher KJ
N Engl J Med (UNITED STATES) Jan 15 1976, 294 (3) p121-4, ISSN
0028-4793 Journal Code: NOW
Languages: ENGLISH
Document type: JOURNAL ARTICLE

8/3/26 (Item 8 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

02155145 76213657
Hereditary deficiency of the fifth component of **complement** in man.
I. Clinical, immunochemical, and family studies.
Rosenfeld SI; Kelly ME; Leddy JP
J Clin Invest (UNITED STATES) Jun 1976, 57 (6) p1626-34, ISSN
0021-9738 Journal Code: HS7
Languages: ENGLISH
Document type: JOURNAL ARTICLE
? t s8/7/11

8/7/11 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1999 Elsevier Science B.V. All rts. reserv.

06685625 EMBASE No: 1996350544
Anti-**C5** monoclonal antibody: A novel anti-inflammatory agent
Expert Opinion on Therapeutic Patents (EXPERT OPIN. THER. PAT.) (United
Kingdom) 1996, 6/11 (1229-1230)
CODEN: EOTPE ISSN: 1354-3776
DOCUMENT TYPE: Journal; Short Survey
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

C5 is a key component of the **complement** system, responsible
for the development of cell lysis and chemotaxis for a variety of cell
types. It plays a key role in the initiation and the maintenance of the
inflammatory response. A monoclonal antibody to mouse **C5** has been
shown to **reduce** polymorphonuclear (PMN) cell infiltrate and preserve
joint structure in a mouse model of **arthritis**, when administered
after disease onset.

```

begin 652,653,654
  04nov99 14:33:57 User208760 Session D1328.3
    $7.75    1.476 DialUnits File5
      $12.40  8 Type(s) in Format  3
    $12.40  8 Types
  $20.15 Estimated cost File5
    $7.65    0.988 DialUnits File73
      $20.50 10 Type(s) in Format  3
    $2.05    1 Type(s) in Format  7
  $22.55 11 Types
  $30.20 Estimated cost File73
    $3.57    1.190 DialUnits File155
      $1.60  8 Type(s) in Format  3
    $1.60  8 Types
  $5.17 Estimated cost File155
    $15.42   1.312 DialUnits File399
      $34.30 14 Type(s) in Format  7
    $34.30 14 Types
  $49.72 Estimated cost File399
    $1.89    0.170 DialUnits File357
  $1.89 Estimated cost File357
    OneSearch, 5 files,  5.136 DialUnits FileOS
  $1.99 TYMNET
  $109.12 Estimated cost this search
  $109.39 Estimated total session cost  5.247 DialUnits

```

SYSTEM:OS - DIALOG OneSearch

```

  File 652:US Patents Fulltext  1971-1979
    (c) format only 1999 The Dialog Corp.
*File 652: Reassignment data now current through 07/09/99
Reexamination, extension, expiration, reinstatement updated weekly.
  File 653:US Patents Fulltext  1980-1989
    (c) format only 1999 The Dialog Corp.
*File 653: Reassignment data now current through 07/09/99.
Reexamination, extension, expiration, reinstatement updated weekly.
  File 654:US Pat.Full.  1990-1999/Nov 02
    (c) format only 1999 The Dialog Corp.
*File 654: Reassignment data current through 07/09/99.

```

Set Items Description

```

---
? s (c5)(30n)(complement) and (arthritis or inflamm?)(20n)(inhibit? or reduc?
or decreas? or treat? or suppress? or therap?)
>>>Operator "(5C)" in invalid position
? s (complement)(30n)(c5) and (arthritis or inflamm?)(20n)(inhibit? or reduc?
or decreas? or treat? or suppress? or therap?)
>>>Operator "(5C)" in invalid position
? s (complement)(30n)(antibod?) and (arthritis or inflamm?)(20n)(inhibit? or
reduc? or decreas? or treat? or suppress? or therap?)
Processing
Processing
Processing
Processing
  45449 COMPLEMENT
  38500 ANTIBOD?
   3206 COMPLEMENT(30N)ANTIBOD?
  13364 ARTHRITIS
  34857 INFLAMM?
  284861 INHIBIT?
 1475306 REDUC?

```

658817 DECREAS?
 609429 TR
 140282 SU SS?
 96910 THERAP?
 21222 (ARTHRITIS OR INFLAMM?)(20N)((((INHIBIT? OR REDUC?) OR
 S1 904 DECREAS?) OR TREAT?) OR SUPPRESS?) OR THERAP?)
 (COMPLEMENT)(30N)(ANTIBOD?) AND (ARTHRITIS OR
 INFLAMM?)(20N)(INHIBIT? OR REDUC? OR DECREAS? OR TREAT?
 OR SUPPRESS? OR THERAP?)
 ? s s1 and c5
 904 S1
 17892 C5
 S2 203 S1 AND C5
 ? s s1 and c5(20n)(antibod?)
 904 S1
 17892 C5
 38500 ANTIBOD?
 106 C5(20N)ANTIBOD?
 S3 27 S1 AND C5(20N)(ANTIBOD?)
 ? t s3/3/all

3/3/1 (Item 1 from file: 653)
 DIALOG(R)File 653:US Patents Fulltext
 (c) format only 1999 The Dialog Corp. All rts. reserv.

01826518

Utility
 HUMAN COMPLEMENT FACTORS AND THEIR THERAPEUTIC USE

PATENT NO.: 4,883,784
 ISSUED: November 28, 1989 (19891128)
 INVENTOR(s): Kaneko, Isao, Tokyo, JP (Japan)
 ASSIGNEE(s): Sankyo Company Limited, (A Non-U.S. Company or Corporation),
 Tokyo, JP (Japan)
 [Assignee Code(s): 74032]
 EXTRA INFO: Expired, effective December 3, 1997 (19971203), recorded in
 O.G. of February 10, 1998 (19980210)
 APPL. NO.: 7-181,309
 FILED: April 13, 1988 (19880413)
 PRIORITY: 60-250187, JP (Japan), November 8, 1985 (19851108)

This is a continuation of application Ser. No. 927,733 filed Nov. 5,
 1986, now abandoned.

FULL TEXT: 282 lines

3/3/2 (Item 2 from file: 653)
 DIALOG(R)File 653:US Patents Fulltext
 (c) format only 1999 The Dialog Corp. All rts. reserv.

01628283

Utility
 PRODUCTS AND METHODS FOR TREATMENT OF CANCER

PATENT NO.: 4,699,783
 ISSUED: October 13, 1987 (19871013)
 INVENTOR(s): Terman, David S., 25371 Outlook Dr., Carmel, CA (California),
 US (United States of America), 93923
 Balint, Joseph P., 169 Crooks Ave., Clifton, NJ (New Jersey),
 US (United States of America), 07011
 Langone, John J., 7735 Candlegreen, Houston, TX (Texas), US
 (United States of America), 77071
 [Assignee Code(s): 68000]
 EXTRA INFO: Assignment transaction [Reassigned], recorded January 4,
 1988 (19880104)

Expired, effective October 13, 1991 (19911013), recorded in
O.G. of September 24, 1991 (19911224)
APPL. NO.: 6-542,23
FILED: October 14, 1983 (19831014)

BACKGROUND OF INVENTIONS

CROSS REFERENCE TO RELATED APPLICATION

The present invention is a continuation-in-part of application Ser. No. 472,362 filed Mar. 11, 1983 now abandoned, which is a continuation-in-part of application Ser. No. 366,436 filed Apr. 7, 1982 now abandoned.

FULL TEXT: 2224 lines

3/3/3 (Item 3 from file: 653)
DIALOG(R)File 653:US Patents Fulltext
(c) format only 1999 The Dialog Corp. All rts. reserv.

01598353

Utility

MURINE MONOCLONAL ANTIBODY COMBINING SITE TO HUMAN C3B RECEPTOR (CR1)

PATENT NO.: 4,672,044
ISSUED: June 09, 1987 (19870609)
INVENTOR(s): Schreiber, Robert D., Encinitas, CA (California), US (United States of America)
ASSIGNEE(s): Scripps Clinic & Research Foundation, (A U.S. Company or Corporation), La Jolla, CA (California), US (United States of America)
[Assignee Code(s): 3325]
EXTRA INFO: Assignment transaction [Reassigned], recorded November 18, 1991 (19911118)
Expired, effective June 9, 1991 (19910609), recorded in O.G. of August 20, 1991 (19910820)
APPL. NO.: 6-644,217
FILED: August 24, 1984 (19840824)

The Government of the United States of America has certain rights in this invention pursuant to Grant No. AI 17354 awarded by the United States Public Health Service.

FULL TEXT: 1372 lines

3/3/4 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02997936

Utility

BENZENE COMPOUND AND PHARMACEUTICAL USE THEREOF

PATENT NO.: 5,948,820
ISSUED: September 07, 1999 (19990907)
INVENTOR(s): Fujita, Tetsuro, Muko, JP (Japan)
Adachi, Kunitomo, Chikujo-gun, JP (Japan)
Kohara, Toshiyuki, Iruma, JP (Japan)
Kiuchi, Masatoshi, Iruma, JP (Japan)
Chiba, Kenji, Chikujo-gun, JP (Japan)
Teshima, Koji, Iruma, JP (Japan)
Mishina, Tadashi, Chikujo-gun, JP (Japan)
ASSIGNEE(s): Yoshitomi Pharmaceutical Industries, Ltd , (A Non-U.S. Company or Corporation), Osaka, JP (Japan)
[Assignee Code(s): 93712]

APPL. NO.: 8-801,390
FILED: February 10, 1997 (19970220)
PRIORITY: 6-19688, JP (Japan), August 22, 1994 (19940822)
7-082934, JP (Japan), April 7, 1995 (19950407)
7-172543, JP (Japan), July 7, 1995 (19950707)

This is a continuation-in-part of PCT-JP95-01654, filed Aug. 22, 1995.

FULL TEXT: 10333 lines

3/3/5 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02987458

Utility
GONOCOCCAL ANTI-IDIOTYPIC ANTIBODIES AND METHODS AND COMPOSITIONS USING THEM

PATENT NO.: 5,939,067
ISSUED: August 17, 1999 (19990817)
INVENTOR(s): Rice, Peter A., 55 Norfolk Rd., Chestnut Hill, MA
(Massachusetts), US (United States of America), 02167
Gulati, Sunita, 14 Wheeler St., Gloucester, MA
(Massachusetts), US (United States of America), 01930
McQuillen, Daniel P., 224 Hillcrest Rd., Needham, MA
(Massachusetts), US (United States of America), 02192
[Assignee Code(s): 68000]
APPL. NO.: 8-908,768
FILED: August 08, 1997 (19970808)

This application is a continuation of U.S. patent application Ser. No. 08-487,414, filed Jun. 7, 1995, now abandoned, which is a continuation of U.S. patent application Ser. No. 08-043,663, filed Apr. 6, 1993, now U.S. Pat. No. 5,476,784.

FULL TEXT: 1967 lines

3/3/6 (Item 3 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02931376

Utility
GONOCOCCAL ANTI-IDIOTYPIC ANTIBODIES AND METHODS AND COMPOSITIONS USING THEM

PATENT NO.: 5,888,509
ISSUED: March 30, 1999 (19990330)
INVENTOR(s): Rice, Peter A., 55 Norfolk Rd., Chestnut Hill, MA
(Massachusetts), US (United States of America), 02167
Gulati, Sunita, 14 Wheeler St., Gloucester, MA
(Massachusetts), US (United States of America), 01930
McQuillen, Daniel P., 224 Hillcrest Rd., Needham, MA
(Massachusetts), US (United States of America), 02192
[Assignee Code(s): 68000]
APPL. NO.: 8-915,304
FILED: August 19, 1997 (19970819)

This is a continuation of U.S. patent application Ser. No. 08-486,722, filed Jun. 7, 1995, now abandoned, which is a division of U.S. patent application Ser. No. 08-043,663, filed Apr. 6, 1993, now U.S. Pat. No. 5,476,784.

FULL TEXT: 1937 lines

3/3/7 (Item 4 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02910741

Utility
HIGH AFFINITY NUCLEIC ACID LIGANDS OF CD4

PATENT NO.: 5,869,641
ISSUED: February 09, 1999 (19990209)
INVENTOR(s): Jayasena, Sumedha, Boulder, CO (Colorado), US (United States of America)
Davis, Kenneth A., Woodside, CA (California), US (United States of America)
Gold, Larry, Boulder, CO (Colorado), US (United States of America)
ASSIGNEE(s): NeXstar Pharmaceuticals, Inc , (A U.S. Company or Corporation)
, Boulder, CO (Colorado), US (United States of America)
[Assignee Code(s): 37214]
APPL. NO.: 8-799,949
FILED: February 14, 1997 (19970214)

This application is a Continuation-in-Part of U.S. patent application Ser. No. 08-428,964, filed Apr. 25, 1995, entitled "Nucleic Acid Ligands", which is a Continuation of U.S. patent application Ser. No. 07-714,131, filed Jun. 10, 1991, entitled "Nucleic Acid Ligands", now issued as U.S. Pat. No. 5,475,096, which is a Continuation-in-Part of U.S. patent application Ser. No. 07-536,428, filed Jun. 11, 1990, entitled "Systematic Evolution of Ligands by Exponential Enrichment", now abandoned.

FULL TEXT: 1383 lines

3/3/8 (Item 5 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02892868

Utility
USE OF C5-SPECIFIC ANTIBODIES FOR REDUCING IMMUNE AND
HEMOSTATIC DYSFUNCTIONS DURING EXTRACORPOREAL CIRCULATION

PATENT NO.: 5,853,722
ISSUED: December 29, 1998 (19981229)
INVENTOR(s): Rollins, Scott, Monroe, CT (Connecticut), US (United States of America)
Smith, Brian R., Madison, CT (Connecticut), US (United States of America)
Squinto, Stephen P., Bethany, CT (Connecticut), US (United States of America)
ASSIGNEE(s): Alexion Pharmaceuticals, Inc , (A U.S. Company or Corporation)
, New Haven, CT (Connecticut), US (United States of America)
Yale University, (A U.S. Company or Corporation), New Haven, CT (Connecticut), US (United States of America)
[Assignee Code(s): 1311; 39924]
APPL. NO.: 8-575,057
FILED: December 21, 1995 (19951221)

This application is a continuation application of application Ser. No. 08-217,391, filed on Mar. 23, 1994 now abandoned.

The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on

reasonable terms as provided for by the terms of Grant No. HL47193 awarded by The National Institutes of Health, Bethesda, Md.

FULL TEXT: 969 lines

3/3/9 (Item 6 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02887789

Utility
MODIFIED HUMAN C3 PROTEINS

PATENT NO.: 5,849,297
ISSUED: December 15, 1998 (19981215)
INVENTOR(s): Harrison, Richard Alexander, Cambridge, GB (United Kingdom).
Great Britian
Farries, Timothy Charles, Cambridge, GB (United Kingdom).Great
Britian
ASSIGNEE(s): Imutran Limited, (A Non-U.S. Company or Corporation), GB
(United Kingdom) Great Britain
APPL. NO.: 8-793,126
FILED: February 07, 1997 (19970207)
PRIORITY: 9418147, GB (United Kingdom), September 8, 1994 (19940908)
9509102, GB (United Kingdom), May 4, 1995 (19950504)

This application is a continuation, of application Ser. No.
PCT-GB95-02121, filed 8 Sep., 1995 .

FULL TEXT: 1792 lines

3/3/10 (Item 7 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02881657

Utility
USE OF CHIMERIC VACCINIA VIRUS COMPLEMENT CONTROL PROTEINS TO INHIBIT
COMPLEMENT

PATENT NO.: 5,843,778
ISSUED: December 01, 1998 (19981201)
INVENTOR(s): Rosengard, Ariella M., Gladwyne, PA (Pennsylvania), US (United
States of America)
Ahearn, Jr. Joseph M., Baltimore, MD (Maryland), US (United
States of America)
Sanfilippo, Alfred P., Baltimore, MD (Maryland), US (United
States of America)
Baldwin, III, William M., Baltimore, MD (Maryland), US (United
States of America)
ASSIGNEE(s): The Johns Hopkins University School of Medicine, (A U.S.
Company or Corporation), Baltimore, MD (Maryland), US (United
States of America)
[Assignee Code(s): 39884]
APPL. NO.: 8-874,978
FILED: June 13, 1997 (19970613)

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made, at least in part, with funds from the Federal
Government awarded through the National Institutes of Health (Grant
HLB31331).

FULL TEXT: 736 lines

3/3/11 (Item 8 file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02799400

Utility

TROVA FOWL POX VIRUS RECOMBINANTS COMPRISING HETEROLOGOUS INSERTS

PATENT NO.: 5,766,599
ISSUED: June 16, 1998 (19980616)
INVENTOR(s): Paoletti, Enzo, Delmar, NY (New York), US (United States of America)
Perkus, Marion E., Altamont, NY (New York), US (United States of America)
Taylor, Jill, Albany, NY (New York), US (United States of America)
Tartaglia, James, Schenectady, NY (New York), US (United States of America)
Norton, Elizabeth K., Latham, NY (New York), US (United States of America)
Riviere, Michel, Ecully, FR (France)
de Taisne, Charles, Lyons, FR (France)
Limbach, Keith J., Troy, NY (New York), US (United States of America)
Johnson, Gerard P., Waterford, NY (New York), US (United States of America)
Pincus, Steven E., East Greenbush, NY (New York), US (United States of America)
Cox, William I., Troy, NY (New York), US (United States of America)
Audonnet, Jean-Christophe Francis, Albany, NY (New York), US (United States of America)
Gettig, Russell Robert, Averill Park, NY (New York), US (United States of America)
ASSIGNEE(s): Virogenetics Corporation, (A U.S. Company or Corporation), Troy, NY (New York), US (United States of America)
[Assignee Code(s): 34766]
APPL. NO.: 8-458,101
FILED: June 01, 1995 (19950601)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08-105,483, filed Aug. 12, 1993, now U.S. Pat. No. 5,494,807 which is a continuation of application Ser. No. 07-847,951, filed Mar. 6, 1992, now abandoned, application Ser. No. 07-847,951, is a continuation-in-part of application Ser. No. 07-713,967, filed Jun. 11, 1991, now abandoned, which in turn is a continuation-in-part of application Ser. No. 07-666,056, filed Mar. 7, 1991, now abandoned, both of which are hereby incorporated herein by reference. Reference is also made to copending U.S. application Ser. Nos. 715,921, filed Jun. 14, 1991, now abandoned, Ser. No. 736,254, filed Jul. 26, 1991, now abandoned, Ser. No. 776,867, filed Oct. 22, 1991, now abandoned, and Ser. No. 820,077, filed Jan. 13, 1992, now abandoned, all of which are hereby incorporated herein by reference.

FULL TEXT: 17399 lines

3/3/12 (Item 9 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02795604

Utility

MODIFIED RECOMBINANT VACCINIA VIRUS AND EXPRESSION VECTORS THEREOF

PATENT NO.: 5,762,900
ISSUED: June 09, 1998 (19980609)
INVENTOR(s): Paoletti, Enzo, Delmar, NY (New York), US (United States of America)
Perkus, Marion E., Altamont, NY (New York), US (United States of America)
Taylor, Jill, Albany, NY (New York), US (United States of America)
Tartaglia, James, Schenectady, NY (New York), US (United States of America)
Norton, Elizabeth K., Latham, NY (New York), US (United States of America)
Riviere, Michel, Ecully, FR (France)
de Taisne, Charles, Lyon, FR (France)
Limbach, Keith J., Troy, NY (New York), US (United States of America)
Johnson, Gerard P., Waterford, NY (New York), US (United States of America)
Pincus, Steven E., East Greenbush, NY (New York), US (United States of America)
Cox, William I., Troy, NY (New York), US (United States of America)
Audonnet, Jean-Christophe Francis, Albany, NY (New York), US (United States of America)
Gettig, Russell Robert, Averill Park, NY (New York), US (United States of America)
ASSIGNEE(s): Virogenetics Corporation, (A U.S. Company or Corporation), Troy, NY (New York), US (United States of America)
[Assignee Code(s): 34766]
APPL. NO.: 8-709,209
FILED: August 21, 1996 (19960821)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08-457,007, filed Jun. 1, 1995, which in turn is a divisional application of Ser. No. 08-105,483, filed Aug. 12, 1993, now U.S. Pat. No. 5,494,807, filed Mar. 6, 1992, now abandoned, which is a continuation-in-part of application Ser. No. 713,976, filed Jun. 11, 1991, now abandoned, which in turn is a continuation-in-part of application Ser. No. 666,056, filed Mar. 7, 1991, now abandoned.

This application is a continuation-in-part of application Ser. No. 07-713,967, filed Jun. 11, 1991 which in turn is a continuation-in-part of application Ser. No. 07-666,056, filed Mar. 7, 1991, both of which are hereby incorporated herein by reference. Reference is also made to copending U.S. applications Ser. Nos. 715,921, filed Jun. 14, 1991, 736,254, filed Jul. 26, 1991, 776,867, filed Oct. 22, 1991, and 820,077, filed Jan. 13, 1992, all of which are hereby incorporated herein by reference.

FULL TEXT: 17589 lines

3/3/13 (Item 10 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02788400

Utility

ALVAC CANARYPOX VIRUS RECOMBINANTS COMPRISING HETEROLOGOUS INSERTS

PATENT NO.: 5,756,103
ISSUED: May 26, 1998 (19980526)

INVENTOR(s): Paoletti, Enzo, Delmar, NY (New York), US (United States of America)
Perkus, ion E., Altamont, NY (New York), US (United States of America)
Taylor, Jill, Albany, NY (New York), US (United States of America)
Tartaglia, James, Schenectady, NY (New York), US (United States of America)
Norton, Elizabeth K., Latham, NY (New York), US (United States of America)
Riviere, Michel, Ecully, FR (France)
de Taisne, Charles, Lyons, FR (France)
Limbach, Keith J., Troy, NY (New York), US (United States of America)
Johnson, Gerard P., Waterford, NY (New York), US (United States of America)
Pincus, Steven E., East Greenbush, NY (New York), US (United States of America)
Cox, William I., Troy, NY (New York), US (United States of America)
Audonnet, Jean-Christophe Francis, Albany, NY (New York), US (United States of America)
Gettig, Russell Robert, Averill Park, NY (New York), US (United States of America)
ASSIGNEE(s): Virogenetics Corporation, (A U.S. Company or Corporation), Troy, NY (New York), US (United States of America)
[Assignee Code(s): 34766]
APPL. NO.: 8-457,007
FILED: June 01, 1995 (19950601)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08-105,483, filed Aug. 12, 1993, U.S. Pat. No. 5,494,807 which is a continuation of application Ser. No. 07-847,951, filed Mar. 6, 1992, now abandoned. Application Ser. No. 07-847,951 is a continuation-in-part of application Ser. No. 07-713,967, filed Jun. 11, 1991, abandoned which in turn is a continuation-in-part of application Ser. No. 07-666,056, filed Mar. 7, 1991, abandoned, both of which are hereby incorporated herein by reference. Reference is also made to U.S. application Ser. Nos. 715,921, filed Jun. 14, 1991, abandoned, 736,254, filed Jul. 26, 1991, abandoned, 776,867, filed Oct. 22, 1991, abandoned, and 820,077, filed Jan. 13, 1992, abandoned, all of which are hereby incorporated herein by reference.

FULL TEXT: 13125 lines

3/3/14 (Item 11 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02747943

Utility
METHOD AND COMPOSITIONS FOR DIRECT CONCENTRATED DELIVERY OF PASSIVE IMMUNITY

PATENT NO.: 5,718,899
ISSUED: February 17, 1998 (19980217)
INVENTOR(s): Gristina, Anthony George, 11605 Deer Forest Rd., Reston, VA (Virginia), US (United States of America), 22094
Myrvik, Quentin Newell, 404 Palmetto Dr., Caswell Beach, NC (North Carolina), US (United States of America), 28465
[Assignee Code(s): 68000]
APPL. NO.: 8-608,817
FILED: February 29, 1996 (19960229)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional patent application of the patent application having U.S. Ser. No. 08-295,482 filed Aug. 25, 1994, now U.S. Pat. No. 5,505,945, which itself was a continuation application of the patent application having U.S. Ser. No. 08-003,305 filed Jan. 12, 1993, now abandoned. In addition, this application is related to the co-pending patent application having Ser. No. 08-441,299 filed May 15, 1995, now U.S. Pat. No. 5,530,102, which itself was a divisional of the patent application having Ser. No. 08-003,305, abandoned. The complete contents of each of these patent applications being herein incorporated by reference.

This invention was made with government support under AR26957 and GM35939, both of which were awarded by the National Institutes of Health. The government has certain rights in the invention.

FULL TEXT: 956 lines

3/3/15 (Item 12 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02735100

Utility
METHODS AND COMPOSITIONS FOR THE DIRECT CONCENTRATED DELIVERY OF PASSIVE
IMMUNITY
[Bactericides and immunoglobulins]

PATENT NO.: 5,707,627
ISSUED: January 13, 1998 (19980113)
INVENTOR(s): Gristina, Anthony George, 11605 Deer Forest Rd., Reston, VA
(Virginia), US (United States of America), 22094
Myrvik, Quentin Newell, 404 Palmetto Dr., Caswell Beach, NC
(North Carolina), US (United States of America), 28465
[Assignee Code(s): 68000]
APPL. NO.: 8-609,912
FILED: February 29, 1996 (19960229)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional patent application of the patent application having U.S. Ser. No. 08-295,482 filed Aug. 25, 1994, now U.S. Pat. No. 5,505,945, which itself was a continuation application of the patent application having U.S. Ser. No. 08-003,305 filed Jan. 12, 1993, now abandoned. In addition, this application is related to the patent application having Ser. No. 08-441,299 filed May 15, 1995, now U.S. Pat. No. 5,530,102, which itself was a divisional of the patent application having Ser. No. 08-003,305. The complete contents of each of these patent applications being herein incorporated by reference.

This invention was made with government support under AR26957 and GM35939, both of which were awarded by the National Institutes of Health. The government has certain rights in the invention.

FULL TEXT: 1033 lines

3/3/16 (Item 13 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02703242

Utility

METHOD FOR PREVENTING COMPLEMENT-DEPENDENT REJECTION OF ORGAN OR TISSUE TRANSPLANTS

[Administering an inhibitor of membrane attack complex formation]

PATENT NO.: 5,679,345

ISSUED: October 21, 1997 (19971021)

INVENTOR(s): Sanfilippo, Alfred P., Baltimore, MD (Maryland), US (United States of America)
Baldwin, III, William M., Baltimore, MD (Maryland), US (United States of America)
Brauer, Robert B., Baltimore, MD (Maryland), US (United States of America)

ASSIGNEE(s): The Johns Hopkins University, (A U.S. Company or Corporation), Baltimore, MD (Maryland), US (United States of America)
[Assignee Code(s): 39884]

APPL. NO.: 8-253,279

FILED: June 02, 1994 (19940602)

The work leading to this invention was supported in part by Grant Nos. AI19368 and AI01092 from the National Institutes of Health. The United States Government may retain certain rights in this invention.

FULL TEXT: 1539 lines

3/3/17 (Item 14 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 1999 The Dialog Corp. All rts. reserv.

02631793

Utility

T CELL RECEPTOR PEPTIDES AS THERAPEUTICS FOR IMMUNE-RELATED DISEASE

PATENT NO.: 5,614,192

ISSUED: March 25, 1997 (19970325)

INVENTOR(s): Vandembark, Arthur A., Portland, OR (Oregon), US (United States of America)

ASSIGNEE(s): Connective Therapeutics, Inc, (A U.S. Company or Corporation),

Connecting through TYMNET

please type your terminal identifier
-2514:02-032-
please log in: dialog

DIALOG: call connected

Logging in to Dialog

DIALOG INFORMATION SERVICES

PLEASE LOGON:

ENTER PASSWORD:

Welcome to DIALOG

Dialog level 99.07.29D

Last logoff: 02nov99 09:50:36

Logon file001 04nov99 14:24:06

ANNOUNCEMENT **** ANNOUNCEMENT **** ANNOUNCEMENT

NEW

***Kompass Mexico (File 586)

***Market Guide Company Financials (File 100)

***Frost & Sullivan Market Engineering (File 767)

RELOADED

***Gale Group PROMT (Files 16, 160)

***Gale Group F&S Index (File 18)

***RAPRA (File 323)

***Gale Group New Product Announcements (File 621)

***Aerospace/Defense Markets & Technology (File 80)

***ICC British Company Directory (File 561)

REMOVED

***A-V Online (File 46)

***Philosopher's Index (File 57)

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<

>>> of new databases, price changes, etc. <<<

* * *

File 1:ERIC 1966-1999/Aug

(c) format only 1999 The Dialog Corporation

*File 1: Updates are delayed owing to technical problems.

File will closed Friday night, 11/5 for reload.

Set Items Description

--- -----

? b 410

04nov99 14:24:11 User208760 Session D1328.1

\$0.20 0.061 DialUnits File1

\$0.20 Estimated cost File1

\$0.01 TYMNET

\$0.21 Estimated cost this search
\$0.21 Estimated total session cost 0.061 DialUnits

File 410:Chronolog(R) 1981-1999 Sep/Oct
(c) 1999 The Dialog Corporation plc

Set Items Description

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 5,73,155,399,357

04nov99 14:24:31 User208760 Session D1328.2

\$0.00 0.050 DialUnits File410

\$0.00 Estimated cost File410

\$0.06 TYMNET

\$0.06 Estimated cost this search

\$0.27 Estimated total session cost 0.112 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-1999/Oct W2

(c) 1999 BIOSIS

File 73:EMBASE 1974-1999/Oct W4

(c) 1999 Elsevier Science B.V.

File 155:MEDLINE(R) 1966-1999/Dec W4

(c) format only 1999 Dialog Corporation

*File 155: Medline updates are complete for 1999.

First update for 2000 will be added in mid-December.

File 399:CA SEARCH(R) 1967-1999/UD=13119

(c) 1999 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement.

RANK charge added; see HELP RATES 399.

File 357:Derwent Biotechnology Abs 1982-1999/Sep B2

(c) 1999 Derwent Publ Ltd

*File 357: Derwent changes DialUnit pricing from May 1, 1999. See
HELP DERWENT for details.

Set Items Description

? e au=wang, yi

Ref Items Index-term

E1 2 AU=WANG, YEYAO

E2 1 AU=WANG, YEZHONG

E3 265 *AU=WANG, YI

E4 2 AU=WANG, YI BING

E5 5 AU=WANG, YI CHANG

E6 3 AU=WANG, YI CHI

E7 4 AU=WANG, YI CHING

E8 2 AU=WANG, YI CHONG

E9 1 AU=WANG, YI CHUN

E10 4 AU=WANG, YI CHUN J.

E11 1 AU=WANG, YI DING

E12 4 AU=WANG, YI F.

Enter P or PAGE for more

? p

Ref Items Index-term

E13 5 AU=WANG, YI FANG

E14 1 AU=WANG, YI FEI

E15 2 AU=WANG, YI FENG

E16 33 AU=WANG, YI FONG

E17 2 AU=WANG, YI FU

E18 5 AU=WANG, YI GUANG

E19 1 AU=WANG, YI GUI

E20	1	AU=WANG, YI HUA
E21	1	AU=WANG, YI HUEI
E22	1	AU=WANG, YI JI
E23	1	AU=WANG, YI JIN
E24	7	AU=WANG, YI LAI

Enter P or PAGE for more

? p

Ref	Items	Index-term
E25	1	AU=WANG, YI LEI
E26	3	AU=WANG, YI LI
E27	1	AU=WANG, YI LING
E28	1	AU=WANG, YI M.
E29	7	AU=WANG, YI MING
E30	1	AU=WANG, YI NING
E31	3	AU=WANG, YI PENG
E32	5	AU=WANG, YI PING
E33	3	AU=WANG, YI QIU
E34	5	AU=WANG, YI RAN
E35	1	AU=WANG, YI REN
E36	1	AU=WANG, YI RU

Enter P or PAGE for more

? p

Ref	Items	Index-term
E37	1	AU=WANG, YI SHUNG
E38	26	AU=WANG, YI TIN
E39	4	AU=WANG, YI WEI
E40	17	AU=WANG, YI XIN
E41	2	AU=WANG, YI XUAN
E42	13	AU=WANG, YI Y.
E43	2	AU=WANG, YI YAO
E44	1	AU=WANG, YI ZHON
E45	3	AU=WANG, YI ZHONG
E46	1	AU=WANG, YI ZUN
E47	1	AU=WANG, YI. Y.
E48	3	AU=WANG, YI-BING

Enter P or PAGE for more

? s e1-e47

2	AU=WANG, YEYAO
1	AU=WANG, YEZHONG
265	AU=WANG, YI
2	AU=WANG, YI BING
5	AU=WANG, YI CHANG
3	AU=WANG, YI CHI
4	AU=WANG, YI CHING
2	AU=WANG, YI CHONG
1	AU=WANG, YI CHUN
4	AU=WANG, YI CHUN J.
1	AU=WANG, YI DING
4	AU=WANG, YI F.
5	AU=WANG, YI FANG
1	AU=WANG, YI FEI
2	AU=WANG, YI FENG
33	AU=WANG, YI FONG
2	AU=WANG, YI FU
5	AU=WANG, YI GUANG
1	AU=WANG, YI GUI
1	AU=WANG, YI HUA
1	AU=WANG, YI HUEI
1	AU=WANG, YI JI
1	AU=WANG, YI JIN
7	AU=WANG, YI LAI

1 AU=WANG, YI LEI
 3 AU=WANG, YI LI
 1 AU=WANG, YI LING
 1 AU=WANG, YI M.
 7 AU=WANG, YI MING
 1 AU=WANG, YI NING
 3 AU=WANG, YI PENG
 5 AU=WANG, YI PING
 3 AU=WANG, YI QIU
 5 AU=WANG, YI RAN
 1 AU=WANG, YI REN
 1 AU=WANG, YI RU
 1 AU=WANG, YI SHUNG
 26 AU=WANG, YI TIN
 4 AU=WANG, YI WEI
 17 AU=WANG, YI XIN
 2 AU=WANG, YI XUAN
 13 AU=WANG, YI Y.
 2 AU=WANG, YI YAO
 1 AU=WANG, YI ZHON
 3 AU=WANG, YI ZHONG
 1 AU=WANG, YI ZUN
 1 AU=WANG, YI. Y.
 S1 457 E1-E47
 ? s s1 and c5 and complement
 457 S1
 18672 C5
 228115 COMPLEMENT
 S2 5 S1 AND C5 AND COMPLEMENT
 ? rd s2
 ...completed examining records
 S3 5 RD S2 (unique items)
 ? t s3/7/all

3/7/1 (Item 1 from file: 399)
 DIALOG(R)File 399:CA SEARCH(R)
 (c) 1999 American Chemical Society. All rts. reserv.

127330281 CA: 127(24)330281f JOURNAL
 Required early complement activation in contact sensitivity with
 generation of local C5-dependent chemotactic activity, and late T cell
 interferon .gamma.: a possible initiating role of B cells
 AUTHOR(S): Tsuji, Ryohei F.; Geba, Gregory P.; Wang, Yi; Kawamoto, Keiko;
 Matis, Louis A.; Askenase, Philip W.
 LOCATION: Noda Institute for Scientific Research, Noda, Japan, 278
 JOURNAL: J. Exp. Med. DATE: 1997 VOLUME: 186 NUMBER: 7 PAGES:
 1015-1026 CODEN: JEMEA V ISSN: 0022-1007 LANGUAGE: English PUBLISHER:
 Rockefeller University Press
 SECTION:
 CA215009 Immunochemistry
 IDENTIFIERS: contact sensitivity complement interferon T lymphocyte
 DESCRIPTORS:
 Allergic contact dermatitis... Antigens... B cell(lymphocyte)... Chemotaxis
 ... Complement... Delayed hypersensitivity... Immunoglobulins... Interferon
 .gamma.... Leukocyte migration... Macrophage... T cell(lymphocyte)...
 required early complement activation in contact sensitivity with
 generation of local C5-dependent chemotactic activity and late T cell
 interferon .gamma.
 CAS REGISTRY NUMBERS:
 80295-53-0 80295-54-1 required early complement activation in contact
 sensitivity with generation of local C5-dependent chemotactic activity
 and late T cell interferon .gamma.

3/7/2 (Item 2 from file: 399)
 DIALOG(R)File 399:CA SEARCH(R)

(c) 1999 American Chemical Society. All rts. reserv.

127120618 CA: 127120618v CONFERENCE PROCEEDING
Amelioration of lupuslike autoimmune disease in NZB/W F1 mice after
treatment with a blocking monoclonal antibody specific for complement
component C5
AUTHOR(S): Wang, Yi; Hu, Qile; Madri, Joseph A.; Rollins, Scott A.;
Chodera, Amy; Matis, Louis A.
LOCATION: Alexion Pharmaceuticals, 25 Science Park, New Haven, CT, 06511,
USA
JOURNAL: Controlling Complement Syst. Novel Drug Dev., (IBC Conf.)
EDITOR: Mazarakis, Helen (Ed), Swart, Sarah Jane (Ed), DATE: 1997
PAGES: 89-109 CODEN: 64QOAM LANGUAGE: English MEETING DATE: 19960000
PUBLISHER: International Business Communications, Southborough, Mass
SECTION:
CA215008 Immunochemistry
IDENTIFIERS: lupus model monoclonal antibody complement C5
DESCRIPTORS:
Monoclonal antibodies...
amelioration of lupus-like autoimmune disease in mice after treatment
with blocking monoclonal antibody to complement component C5
Glomerulonephritis...
immune complex; terminal complement cascade role in lupus erythematosus
model
Lupus erythematosus...
terminal complement cascade role in lupus erythematosus model
CAS REGISTRY NUMBERS:
80295-53-0 amelioration of lupus-like autoimmune disease in mice after
treatment with blocking monoclonal antibody to complement component C5
82986-89-8 terminal complement cascade role in lupus erythematosus model

3/7/3 (Item 3 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 1999 American Chemical Society. All rts. reserv.

125165528 CA: 125(13)165528r JOURNAL
Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after
treatment with a blocking monoclonal antibody specific for complement
component C5
AUTHOR(S): Wang, Yi; Hu, Qile; Madri, Joseph A.; Rollins, Scott A.;
Chodera, Amy; Matis, Louis A.
LOCATION: Immunobiology Program, Alexion Pharmaceuticals, Inc., New Haven
, CT, 06511, USA
JOURNAL: Proc. Natl. Acad. Sci. U. S. A. DATE: 1996 VOLUME: 93
NUMBER: 16 PAGES: 8563-8568 CODEN: PNASA6 ISSN: 0027-8424 LANGUAGE:
English
SECTION:
CA215008 Immunochemistry
IDENTIFIERS: lupus model monoclonal antibody complement C5
DESCRIPTORS:
Antibodies, monoclonal...
amelioration of lupus-like autoimmune disease in mice after treatment
with blocking monoclonal antibody to complement component C5
Kidney, disease, immune complex glomerulonephritis... Lupus erythematosus...
terminal complement cascade role in lupus erythematosus model
CAS REGISTRY NUMBERS:
80295-53-0 amelioration of lupus-like autoimmune disease in mice after
treatment with blocking monoclonal antibody to complement component C5
82986-89-8 terminal complement cascade role in lupus erythematosus model

3/7/4 (Item 4 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 1999 American Chemical Society. All rts. reserv.

125026270 CA: 125(3)26270n PATENT
Methods for the treatment of inflammatory joint disease with compounds
that block complement component C5
INVENTOR(AUTHOR): Wang, Yi; Matis, Louis
LOCATION: USA
ASSIGNEE: Alexion Pharmaceuticals, Inc.
PATENT: PCT International ; WO 9609043 A1 DATE: 960328
APPLICATION: WO 95US12404 (950921) *US 311489 (940923)
PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-031/395A;
A61K-031/34B; C07D-307/94B; C07K-016/18B; C07K-016/40B
DESIGNATED COUNTRIES: AU; CA; JP DESIGNATED REGIONAL: AT; BE; CH; DE; DK
; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
SECTION:
CA201007 Pharmacology
CA215XXX Immunochemistry
IDENTIFIERS: complement C5 blocker antiinflammatory arthritis, monoclonal
antibody complement C5 antiarthritic
DESCRIPTORS:
Antibodies, monoclonal...
anti-C5; complement C5 blockers for treatment of inflammatory joint
disease
Cytolysis...
by complement; complement C5 blockers for treatment of inflammatory
joint disease
Inflammation inhibitors... Inflammation inhibitors, antiarthritics...
Joint, anatomical, disease, inflammation...
complement C5 blockers for treatment of inflammatory joint disease
Blood serum... Blood...
complement C5 blockers for treatment of inflammatory joint disease in
relation to redn. of cell-lysing ability of complement in blood-derived
fluid
Synovial fluid...
complement C5 blockers for treatment of inflammatory joint disease in
relation to redn. of cell-lysing ability of complement in synovial
fluid
Complement...
cytolysis by; complement C5 blockers for treatment of inflammatory
joint disease
CAS REGISTRY NUMBERS:
80295-53-0 80295-54-1 80295-55-2 82986-89-8 complement C5 blockers for
treatment of inflammatory joint disease

3/7/5 (Item 5 from file: 399)
DIALOG(R) File 399: CA SEARCH(R)
(c) 1999 American Chemical Society. All rts. reserv.

123196481 CA: 123(15)196481h JOURNAL
Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis
and ameliorates established disease
AUTHOR(S): Wang, Yi; Rollins, Scott A.; Madri, Joseph A.; Matis, Louis A.
LOCATION: Immunobiol. Program, Alexion Pharmaceuticals, Inc., New Haven,
CT, 06511, USA
JOURNAL: Proc. Natl. Acad. Sci. U. S. A. DATE: 1995 VOLUME: 92
NUMBER: 19 PAGES: 8955-9 CODEN: PNASA6 ISSN: 0027-8424 LANGUAGE:
English
SECTION:
CA215008 Immunochemistry
IDENTIFIERS: arthritis C5 complement monoclonal antibody
DESCRIPTORS:
Antibodies, monoclonal... Arthritis... Arthritis, rheumatoid...
Collagens, type II, biological studies...
anti-C5 complement monoclonal antibody therapy prevents
collagen-induced arthritis and ameliorates established disease
CAS REGISTRY NUMBERS:
80295-53-0 anti-C5 complement monoclonal antibody therapy prevents

collagen-induced arthritis and ameliorates established disease
? e au=atis, louis

Ref	Items	Index-term
E1	6	AU=MATIS, L. A.
E2	1	AU=MATIS, LOU
E3	9	*AU=MATIS, LOUIS
E4	82	AU=MATIS, LOUIS A.
E5	1	AU=MATIS, M.
E6	1	AU=MATIS, M. I.
E7	4	AU=MATIS, P.
E8	5	AU=MATIS, PAUL
E9	2	AU=MATIS, SHARON
E10	3	AU=MATIS, SHERRI
E11	2	AU=MATIS, SHERRI A.
E12	3	AU=MATIS, U.

Enter P or PAGE for more

? s el-e4

6	AU=MATIS, L. A.
1	AU=MATIS, LOU
9	AU=MATIS, LOUIS
82	AU=MATIS, LOUIS A.
S4	98 E1-E4

? rd s4

...examined 50 records (50)

...completed examining records

S5 96 RD S4 (unique items)

? s s5 and complement and c5

96	S5
228115	COMPLEMENT
18672	C5

S6 9 S5 AND COMPLEMENT AND C5

? t s6/7/all

6/7/1 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 1999 American Chemical Society. All rts. reserv.

129160438 CA: 129(13)160438j JOURNAL

Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy

AUTHOR(S): Vakeva, Antti P.; Agah, Azin; Rollins, Scott A.; Matis, Louis A.; Li, Lan; Stahl, Gregory L.

LOCATION: Haartman Institute, Department of Bacteriology and Immunology, University of Helsinki, Finland

JOURNAL: Circulation DATE: 1998 VOLUME: 97 NUMBER: 22 PAGES: 2259-2267 CODEN: CIRCAZ ISSN: 0009-7322 LANGUAGE: English PUBLISHER: Williams & Wilkins

SECTION:

CA215004 Immunochemistry

CA214XXX Mammalian Pathological Biochemistry

IDENTIFIERS: heart ischemia reperfusion apoptosis complement, myocardial infarction apoptosis complement

DESCRIPTORS:

Apoptosis... Myocardial infarction... Myocardial ischemia... Neutrophil chemotaxis... Reperfusion injury...

myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of terminal complement components and inhibition by anti-C5 therapy

CAS REGISTRY NUMBERS:

80295-43-8 80295-54-1 82986-89-8 myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of terminal complement components and inhibition by anti-C5 therapy

6/7/2 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1999 American Chemical Society. All rts. reserv.

127330281 CA: 127(24)330281f JOURNAL
Required early complement activation in contact sensitivity with
generation of local C5-dependent chemotactic activity, and late T cell
interferon .gamma.: a possible initiating role of B cells
AUTHOR(S): Tsuji, Ryohei F.; Geba, Gregory P.; Wang, Yi; Kawamoto, Keiko;
Matis, Louis A.; Askenase, Philip W.
LOCATION: Noda Institute for Scientific Research, Noda, Japan, 278
JOURNAL: J. Exp. Med. DATE: 1997 VOLUME: 186 NUMBER: 7 PAGES:
1015-1026 CODEN: JEMEAV ISSN: 0022-1007 LANGUAGE: English PUBLISHER:
Rockefeller University Press
SECTION:
CA215009 Immunochemistry
IDENTIFIERS: contact sensitivity complement interferon T lymphocyte
DESCRIPTORS:
Allergic contact dermatitis... Antigens... B cell(lymphocyte)... Chemotaxis
... Complement... Delayed hypersensitivity... Immunoglobulins... Interferon
.gamma.... Leukocyte migration... Macrophage... T cell(lymphocyte)...
required early complement activation in contact sensitivity with
generation of local C5-dependent chemotactic activity and late T cell
interferon .gamma.
CAS REGISTRY NUMBERS:
80295-53-0 80295-54-1 required early complement activation in contact
sensitivity with generation of local C5-dependent chemotactic activity
and late T cell interferon .gamma.

6/7/3 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1999 American Chemical Society. All rts. reserv.

127120618 CA: 127(9)120618v CONFERENCE PROCEEDING
Amelioration of lupuslike autoimmune disease in NZB/W F1 mice after
treatment with a blocking monoclonal antibody specific for complement
component C5
AUTHOR(S): Wang, Yi; Hu, Qile; Madri, Joseph A.; Rollins, Scott A.;
Chodera, Amy; Matis, Louis A.
LOCATION: Alexion Pharmaceuticals, 25 Science Park, New Haven, CT, 06511,
USA
JOURNAL: Controlling Complement Syst. Novel Drug Dev., (IBC Conf.)
EDITOR: Mazarakis, Helen (Ed), Swart, Sarah Jane (Ed), DATE: 1997
PAGES: 89-109 CODEN: 64QOAM LANGUAGE: English MEETING DATE: 19960000
PUBLISHER: International Business Communications, Southborough, Mass
SECTION:
CA215008 Immunochemistry
IDENTIFIERS: lupus model monoclonal antibody complement C5
DESCRIPTORS:
Monoclonal antibodies...
amelioration of lupus-like autoimmune disease in mice after treatment
with blocking monoclonal antibody to complement component C5
Glomerulonephritis...
immune complex; terminal complement cascade role in lupus erythematosus
model
Lupus erythematosus...
terminal complement cascade role in lupus erythematosus model
CAS REGISTRY NUMBERS:
80295-53-0 amelioration of lupus-like autoimmune disease in mice after
treatment with blocking monoclonal antibody to complement component C5
82986-89-8 terminal complement cascade role in lupus erythematosus model

6/7/4 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 1999 American Chemical Society. All rts. reserv.

127079964 CA: 127(6)79964q JOURNAL

Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv

AUTHOR(S): Thomas, Thomas C.; Rollins, Scott A.; Rother, Russell P.; Giannoni, Michelle A.; Hartman, Sandra L.; Elliott, Eileen A.; Nye, Steven H.; Matis, Louis A.; Squinto, Stephen P.; Evans, Mark J.

LOCATION: Alexion Pharmaceuticals, New Haven, CT, 06511, USA

JOURNAL: Mol. Immunol. DATE: 1997 VOLUME: 33 NUMBER: 17/18 PAGES: 1389-1401 CODEN: MOIMD5 ISSN: 0161-5890 PUBLISHER ITEM IDENTIFIER: 0161-5890(96)00078-8 LANGUAGE: English MEETING DATE: 19960000

PUBLISHER: Elsevier

SECTION:

CA215003 Immunochemistry

IDENTIFIERS: complement C5 humanized antibody Fv, single chain Fv antibody complement C5

DESCRIPTORS:

Complement activation...

complement activity inhibition by humanized anti-C5 antibody and single-chain Fv

Humanized antibodies...

monoclonal; complement activity inhibition by humanized anti-C5 antibody and single-chain Fv

Protein sequences...

of anti-complement C5 antibody 5G1.1 heavy and light chain variable regions and single-chain Fv mol. derived from it

DNA sequences...

of anti-complement C5 antibody 5G1.1 heavy and light chain variable regions genes

Antibodies...

single-chain Fv; complement activity inhibition by humanized anti-C5 antibody and single-chain Fv

CAS REGISTRY NUMBERS:

80295-53-0 complement activity inhibition by humanized anti-C5 antibody and single-chain Fv

6/7/5 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 1999 American Chemical Society. All rts. reserv.

125165528 CA: 125(13)165528r JOURNAL

Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5

AUTHOR(S): Wang, Yi; Hu, Qile; Madri, Joseph A.; Rollins, Scott A.; Chodera, Amy; Matis, Louis A.

LOCATION: Immunobiology Program, Alexion Pharmaceuticals, Inc., New Haven, CT, 06511, USA

JOURNAL: Proc. Natl. Acad. Sci. U. S. A. DATE: 1996 VOLUME: 93

NUMBER: 16 PAGES: 8563-8568 CODEN: PNASA6 ISSN: 0027-8424 LANGUAGE: English

SECTION:

CA215008 Immunochemistry

IDENTIFIERS: lupus model monoclonal antibody complement C5

DESCRIPTORS:

Antibodies, monoclonal...

amelioration of lupus-like autoimmune disease in mice after treatment with blocking monoclonal antibody to complement component C5

Kidney, disease, immune complex glomerulonephritis... Lupus erythematosus... terminal complement cascade role in lupus erythematosus model

CAS REGISTRY NUMBERS:

80295-53-0 amelioration of lupus-like autoimmune disease in mice after treatment with blocking monoclonal antibody to complement component C5

6/7/6 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1999 American Chemical Society. All rts. reserv.

125026270 CA: 125(3)26270n PATENT
Methods for the treatment of inflammatory joint disease with compounds
that block complement component C5
INVENTOR(AUTHOR): Wang, Yi; Matis, Louis
LOCATION: USA
ASSIGNEE: Alexion Pharmaceuticals, Inc.
PATENT: PCT International ; WO 9609043 A1 DATE: 960328
APPLICATION: WO 95US12404 (950921) *US 311489 (940923)
PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-031/395A;
A61K-031/34B; C07D-307/94B; C07K-016/18B; C07K-016/40B
DESIGNATED COUNTRIES: AU; CA; JP DESIGNATED REGIONAL: AT; BE; CH; DE; DK
; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
SECTION:
CA201007 Pharmacology
CA215XXX Immunochemistry
IDENTIFIERS: complement C5 blocker antiinflammatory arthritis, monoclonal
antibody complement C5 antiarthritic
DESCRIPTORS:
Antibodies,monoclonal...
anti-C5; complement C5 blockers for treatment of inflammatory joint
disease
Cytolysis...
by complement; complement C5 blockers for treatment of inflammatory
joint disease
Inflammation inhibitors... Inflammation inhibitors,antiarthritics...
Joint,anatomical, disease, inflammation...
complement C5 blockers for treatment of inflammatory joint disease
Blood serum... Blood...
complement C5 blockers for treatment of inflammatory joint disease in
relation to redn. of cell-lysing ability of complement in blood-derived
fluid
Synovial fluid...
complement C5 blockers for treatment of inflammatory joint disease in
relation to redn. of cell-lysing ability of complement in synovial
fluid
Complement...
cytolysis by; complement C5 blockers for treatment of inflammatory
joint disease
CAS REGISTRY NUMBERS:
80295-53-0 80295-54-1 80295-55-2 82986-89-8 complement C5 blockers for
treatment of inflammatory joint disease

6/7/7 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1999 American Chemical Society. All rts. reserv.

124143157 CA: 124(11)143157w JOURNAL
Monoclonal antibodies directed against human C5 and C8 block
complement-mediated damage of xenogeneic cells and organs
AUTHOR(S): Rollins, Scott A.; Matis, Louis A.; Springhorn, Jeremy P.;
Setter, Eva; Wolff, Dennis W.
LOCATION: Department of Immunobiology, Alexion Pharmaceuticals, Inc., New
haven, CT, 06511, USA
JOURNAL: Transplantation DATE: 1995 VOLUME: 60 NUMBER: 11 PAGES:
1284-92 CODEN: TRPLAU ISSN: 0041-1337 LANGUAGE: English
SECTION:
CA215004 Immunochemistry
IDENTIFIERS: monoclonal antibody complement C5 C8

DESCRIPTORS:

Antibodies, monoclonal... Blood vessel, disease, endothe , injury...
Complement... Cytolys... Heart, disease, injury...
monoclonal antibodies to human C5 and C8 block complement-mediated
damage of xenogeneic cells and organs
Transplant and Transplantation, xeno-...
monoclonal antibodies to human C5 and C8 block complement-mediated
damage of xenogeneic cells and organs in relation to
CAS REGISTRY NUMBERS:
80295-53-0 80295-58-5 monoclonal antibodies to human C5 and C8 block
complement-mediated damage of xenogeneic cells and organs
80295-54-1 role of C5a in complement-mediated damage of xenogeneic cells
and organs
82986-89-8 role of C5b-9 in complement-mediated damage of xenogeneic cells
and organs

6/7/8 (Item 8 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 1999 American Chemical Society. All rts. reserv.

124143156 CA: 124(11)143156v JOURNAL

Complement inhibition with an anti-C5 monoclonal antibody prevents acute
cardiac tissue injury in an ex vivo model of pig-to-human
xenotransplantation

AUTHOR(S): Kroshus, Timothy J.; Rollins, Scott A.; Dalmasso, Agustin P.;
Elliott, Eileen A.; Matis, Louis A.; Squinto, Stephen P.; Bolman, R.
Morton, III

LOCATION: Department of Surgery, University of Minnesota, Minneapolis, MN
, USA

JOURNAL: Transplantation DATE: 1995 VOLUME: 60 NUMBER: 11 PAGES:
1194-202 CODEN: TRPLAU ISSN: 0041-1337 LANGUAGE: English

SECTION:

CA215004 Immunochemistry

IDENTIFIERS: cardiac xenotransplant complement monoclonal antibody

DESCRIPTORS:

Antibodies, monoclonal... Complement... Heart, xenotransplant... Swine...
Transplant and Transplantation, xeno-...

complement inhibition with an anti-C5 monoclonal antibody prevents
acute cardiac tissue injury in an ex vivo model of pig-to-human
xenotransplantation

CAS REGISTRY NUMBERS:

80295-54-1 complement inhibition with an anti-C5 monoclonal antibody
prevents acute cardiac tissue injury in an ex vivo model of
pig-to-human xenotransplantation

82986-89-8 role of complement C5b-9 in acute cardiac tissue injury in an
ex vivo model of pig-to-human xenotransplantation

6/7/9 (Item 9 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 1999 American Chemical Society. All rts. reserv.

124127101 CA: 124(10)127101t PATENT

Anti-complement C5 antibodies for the treatment of glomerulonephritis and
other inflammatory diseases

INVENTOR(AUTHOR): Evans, Mark J.; Matis, Louis; Mueller, Eileen Elliott;
Nye, Steven H.; Rollins, Scott; Rother, Russell P.; Springhorn, Jeremy P.;
Squinto, Stephen P.; Thomas, Thomas C.; et al.

LOCATION: USA

ASSIGNEE: Alexion Pharmaceuticals, Inc.

PATENT: PCT International ; WO 9529697 A1 DATE: 951109

APPLICATION: WO 95US5688 (950501) *US 236208 (940502)

PAGES: 159 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/36A;
A61K-039/00B; A61K-039/395B; C07K-014/00B; C07K-014/75B; C07K-016/00B;
C07K-016/18B; C07K-016/36B; C07K-016/46B; C12N-005/10B; C12N-005/20B;

02 The Dialog Corporation

Set Items Description

Cost is in DialUnits

? b 410

20jan02 09:45:57 User208760 Session D1993.1

\$0.24 0.069 DialUnits File1

\$0.24 Estimated cost File1

\$0.24 Estimated cost this search

\$0.24 Estimated total session cost 0.069 DialUnits

File 410:Chronolog(R) 1981-2002/Jan

(c) 2002 The Dialog Corporation

Set Items Description

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 5,73,155,399

20jan02 09:46:03 User208760 Session D1993.2

\$0.00 0.067 DialUnits File410

\$0.00 Estimated cost File410

\$0.00 Estimated cost this search

\$0.24 Estimated total session cost 0.135 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2002/Jan W2

(c) 2002 BIOSIS

File 73:EMBASE 1974-2002/Jan W2

(c) 2002 Elsevier Science B.V.

*File 73: For information about Explode feature please
see Help News73.

File 155:MEDLINE(R) 1966-2002/JAN W3

*File 155: File temporarily is not updating. The updating will
resume by the end of January 2002.

File 399:CA SEARCH(R) 1967-2001/UD=13603

(c) 2002 AMERICAN CHEMICAL SOCIETY

*File 399: Use is subject to the terms of your user/customer agreement.
RANK charge added; see HELP RATES 399.

Set Items Description

? e au=matix louis ?

Ref	Items	Index-term
E1	1	AU=MATIVOS IUP
E2	3	AU=MATIWADE P S
E3	0	*AU=MATIX LOUIS ?
E4	1	AU=MATIX P A
E5	1	AU=MATIX P.A.
E6	1	AU=MATIX PA
E7	1	AU=MATIX, PATRICIA A.
E8	1	AU=MATIYA O
E9	1	AU=MATYASEVICH L M
E10	7	AU=MATYASEVICH, A. M.
E11	26	AU=MATYASEVICH, V. N.
E12	1	AU=MATYASH I M

Enter P or PAGE for more
? e au=wang yi ?

Ref	Items	Index-term
E1	248	AU=WANG YH
E2	167	AU=WANG YI
E3	0	*AU=WANG YI ?
E4	1	AU=WANG YI CHEN HAN
E5	1	AU=WANG YI ET@AL
E6	1	AU=WANG YI FANG
E7	2	AU=WANG YI FEI
E8	1	AU=WANG YI HONG
E9	1	AU=WANG YI LI JI-YOU
E10	1	AU=WANG YI NING
E11	1	AU=WANG YI P
E12	4	AU=WANG YI PING

Enter P or PAGE for more
? p

Ref	Items	Index-term
E13	10	AU=WANG YI RAN
E14	3	AU=WANG YI Y
E15	1	AU=WANG YI. C.
E16	1	AU=WANG YI. Y.
E17	1	AU=WANG YI. Z.
E18	1	AU=WANG YI-CHEN
E19	2	AU=WANG YI-CHENG
E20	1	AU=WANG YI-CHI
E21	1	AU=WANG YI-CHIEH
E22	1	AU=WANG YI-CHIEN
E23	10	AU=WANG YI-CHING
E24	7	AU=WANG YI-CHONG

Enter P or PAGE for more
? s e2

S1 167 AU="WANG YI"
? s s1 and c5

167 S1
21104 C5
S2 12 S1 AND C5
? rd s2

...completed examining records
S3 11 RD S2 (unique items)
? t s3/3/all

3/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13361577 BIOSIS NO.: 200100568726
The allogeneic T and B cell response is strongly dependent on complement components C3 and C4.
AUTHOR: Marsh James E; Farmer Christopher K T; Jurcevic Stipo; Wang Yi; Carroll Michael C; Sacks Steven H(a)
AUTHOR ADDRESS: (a)Department of Nephrology and Transplantation, Guy's Hospital, Floor 5, Thomas Guy House, London, SE1 9RT:
steven.sacks@kcl.ac.uk**UK

JOURNAL: Transplantation (Baltimore) 72 (7):p1310-1318 October 15, 2001
MEDIUM: print
ISSN: 0041-1337
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

3/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12891590 BIOSIS NO.: 200100098739
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis.
AUTHOR: Wang Yi(a); Matis Louis; Rollins Scott
AUTHOR ADDRESS: (a)Orange, CT**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1235 (2):pNo Pagination June 13, 2000
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

3/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12624079 BIOSIS NO.: 200000377581
A role for complement in antibody-mediated inflammation: C5 deficient DBA/1 mice are resistant to collagen-induced arthritis.
AUTHOR: Wang Yi(a); Kristan Jane(a); Hao Liming; Lenkoski Catherine S(a); Shen Yamin(a); Matis Louis A(a)
AUTHOR ADDRESS: (a)Alexion Pharmaceuticals, Inc., 25 Science Park, Suite 360, New Haven, CT, 06511**USA
JOURNAL: Immunopharmacology 49 (1-2):p19 August, 2000
MEDIUM: print
CONFERENCE/MEETING: XVIIIth International Complement Workshop Salt Lake City, Utah, USA July 23-27, 2000
ISSN: 0162-3109
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

3/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12561551 BIOSIS NO.: 200000315053
Predominant role for C5b-9 in renal ischemia/reperfusion injury.
AUTHOR: Zhou Wuding; Farrar Conrad A; Abe Katsushige; Pratt Julian R; Marsh James E; Wang Yi; Stahl Gregory L; Sacks Steven H
AUTHOR ADDRESS: (a)Department of Nephrology and Transplantation, Guy's Hospital, King's College London, St. Thomas Street, 5th Floor, Thomas Guy House, London, SE1 9RT**UK
JOURNAL: Journal of Clinical Investigation 105 (10):p1363-1371 May, 2000
MEDIUM: print
ISSN: 0021-9738
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

LANGUAGE: English
SUMMARY LANGUAGE: English

3/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

11687516 BIOSIS NO.: 199800469247
Effect of anti-IL10 and anti-C5 on human anti-DS DNA antibody induced
kidney damage.
AUTHOR: Ravirajan Chelliah T(a); **Wang Yi**; Matis Louis; Isenberg David
A(a)
AUTHOR ADDRESS: (a)Bloomsbury Rheumatol. Unit, Univ. Coll. London, London
W1P 9PG**UK
JOURNAL: Arthritis & Rheumatism 41 (9 SUPPL.):pS177 Sept., 1998
CONFERENCE/MEETING: 62nd National Scientific Meeting of the American
College of Rheumatology and the 33rd National Scientific Meeting of the
Association of Rheumatology Health Professionals San Diego, California,
USA November 8-12, 1998
SPONSOR: American College of Rheumatology
ISSN: 0004-3591
RECORD TYPE: Citation
LANGUAGE: English

3/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

11179814 BIOSIS NO.: 199799800959
Required early complement activation in contact sensitivity with generation
of local C5-dependent chemotactic activity, and late T cell
interferon gamma: A possible initiating role of B cells.
AUTHOR: Tsuji Ryohei F(a); Geba Gregory P; **Wang Yi**; Kawamoto Keiko;
Matis Louis A; Askenase Philip W
AUTHOR ADDRESS: (a)Noda Inst. Sci. Res., 399 Noda, Noda-shi, Chiba-ken 278
**Japan
JOURNAL: Journal of Experimental Medicine 186 (7):p1015-1026 1997
ISSN: 0022-1007
RECORD TYPE: Abstract
LANGUAGE: English

3/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10603122 BIOSIS NO.: 199699224267
Subcutaneous administration of anti-C5 monoclonal antibody induces
systemic complement inhibition and ameliorates immune complex mediated
inflammatory responses.
AUTHOR: **Wang Yi**(a); Hu Qile(a); Kristan Jane(a); Rollins Scott(a);
Evans Mark(a); Madri Joe; Matis Loui(a)
AUTHOR ADDRESS: (a)Alexion Pharm. Inc., 25 Science Park, New Haven, CT
06511**USA
JOURNAL: Arthritis & Rheumatism 39 (9 SUPPL.):pS245 1996
CONFERENCE/MEETING: 60th National Scientific Meeting of the American
College of Rheumatology and the 31st National Scientific Meeting of the
Association of Rheumatology Health Professionals Orlando, Florida, USA
October 18-22, 1996
ISSN: 0004-3591
RECORD TYPE: Citation
LANGUAGE: English

3/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10514607 BIOSIS NO.: 199699135752
Amelioration of lupus-like autoimmune disease in NZB/W F-1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
AUTHOR: **Wang Yi**(a); Hu Qile; Madri Joseph A; Rollins Scott A; Chodera Amy; Matis Louis A
AUTHOR ADDRESS: (a)Immunobiol. Program, Alexion Pharmaceuticals, Inc., New Haven, CT 06511**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 93 (16):p8563-8568 1996
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

3/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10081311 BIOSIS NO.: 199598536229
Treatment of immune-complex mediated glomerulonephritis with C5 specific monoclonal antibody.
AUTHOR: **Wang Yi**; Hu Qile(a); Rollins Scott(a); Madri Joe; Matis Louis (a)
AUTHOR ADDRESS: (a)Alexion Pharmaceutical Inc., 25 Science Park, New Haven, CT 06511**USA
JOURNAL: Arthritis & Rheumatism 38 (9 SUPPL.):pS390 1995
CONFERENCE/MEETING: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals San Francisco, California, USA October 21-26, 1995
ISSN: 0004-3591
RECORD TYPE: Citation
LANGUAGE: English

3/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10081205 BIOSIS NO.: 199598536123
Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.
AUTHOR: **Wang Yi**(a); Rollins Scott(a); Madri Joe; Matis Louis(a)
AUTHOR ADDRESS: (a)Alexion Pharmaceutical Inc., 25 Science Park, New Haven, CT 06511**USA
JOURNAL: Arthritis & Rheumatism 38 (9 SUPPL.):pS372 1995
CONFERENCE/MEETING: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals San Francisco, California, USA October 21-26, 1995
ISSN: 0004-3591
RECORD TYPE: Citation
LANGUAGE: English

3/3/11 (Item 11 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09885750 BIOSIS NO.: 199598340668

Blockade of C5 prevents the development of collagen induced arthritis
and reduces established joint inflammation.

AUTHOR: Wang Yi; Rollins Scott; Matis Louis

AUTHOR ADDRESS: Alexion Pharm. Inc., 25 Science Park, New Haven, CT 06511
**USA

JOURNAL: Journal of Cellular Biochemistry Supplement 0 (21A):p157 1995

CONFERENCE/MEETING: Keystone Symposium on Control and Manipulation of the
Immune Response Taos, New Mexico, USA March 16-22, 1995

ISSN: 0733-1959

RECORD TYPE: Citation

LANGUAGE: English

? s 5g1? anc c5

S4 0 5G1? ANC C5
? s 5g1? and c5

94 5G1?
21104 C5
S5 5 5G1? AND C5
? rd s5

...completed examining records

S6 2 RD S5 (unique items)
? t s6/3/all

6/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10974348 BIOSIS NO.: 199799595493

Inhibition of complement activity by humanized anti-C5 antibody and
single-chain Fv.

AUTHOR: Thomas Thomas C(a); Rollins Scott A; Rother Russell P; Giannoni
Michelle A; Hartman Sandra L; Elliott Eileen A; Nye Steven H; Matis Louis
A; Squinto Stephen P; Evans Mark J

AUTHOR ADDRESS: (a)Alexion Pharmaceuticals, 25 Science Park, New Haven, CT
06511**USA

JOURNAL: Molecular Immunology 33 (17-18):p1389-1401

ISSN: 0161-5890

RECORD TYPE: Abstract

LANGUAGE: English

6/3/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

11232390 EMBASE No: 2001244886

Recent advances in the management of adult myositis
Fam A.G.

A.G. Fam, Sunnybrook/Women's College, Health Sciences Centre, 2075
Bayview Avenue, Toronto, Ont. M4N 3M5 Canada

AUTHOR EMAIL: adel.fam@swchsc.on.ca

Expert Opinion on Investigational Drugs (EXPERT OPIN. INVEST. DRUGS) (
United Kingdom) 2001, 10/7 (1265-1277)

CODEN: EOIDE ISSN: 1354-3784

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 62

? s c5(10n)antibod?(20n) (inhibit? or block? or therap? or treat? or suppress? or prevent? or antagoni?)

Processing
Processing
Processing

21104 C5
1674657 ANTIBOD?
3404661 INHIBIT?
1072767 BLOCK?
5051449 THERAP?
5461078 TREAT?
679654 SUPPRESS?
1735637 PREVENT?
903896 ANTAGONI?
S7 445 C5(10N)ANTIBOD?(20N) (INHIBIT? OR BLOCK? OR THERAP? OR
TREAT? OR SUPPRESS? OR PREVENT? OR ANTAGONI?)

? s s7 and py=1992

445 S7
1828395 PY=1992
S8 11 S7 AND PY=1992
? rd s8

...completed examining records
S9 6 RD S8 (unique items)
? t s9/3/all

9/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08377954 BIOSIS NO.: 000094108458
FORMATION AND STRUCTURE OF THE C5B-7 COMPLEX OF THE LYTIC PATHWAY OF
COMPLEMENT
AUTHOR: DISCIPIO R G
AUTHOR ADDRESS: DEP. IMMUNOLOGY IMM18, RESEARCH INSTITUTE SCRIPPS CLINIC,
10666 N. TORREY PINES RD., LA JOLLA, CALIF. 92037.
JOURNAL: J BIOL CHEM 267 (24). 1992. 17087-17094. 1992
FULL JOURNAL NAME: Journal of Biological Chemistry
CODEN: JBCHA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

9/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08373609 BIOSIS NO.: 000094104113
A MONOCLONAL ANTIBODY NMC-VIII-10 TO FACTOR VIII LIGHT CHAIN RECOGNIZING
GLU-1675-GLU-1684 INHIBITS FACTOR VIII BINDING TO ENDOGENOUS VON
WILLEBRAND FACTOR IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS
AUTHOR: SHIMA M; YOSHIOKA A; NAKAJIMA M; NAKAI H; FUKUI H
AUTHOR ADDRESS: DEP. PAEDIATRICS, NARA MEDICAL COLLEGE, 840 SHIJO-CHO,
KASHIHARA CITY, NARA, JPN.
JOURNAL: BR J HAEMATOL 81 (4). 1992. 533-538. 1992
FULL JOURNAL NAME: British Journal of Haematology
CODEN: BJHEA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

9/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08064092 BIOSIS NO.: 000093085540
BACTERICIDAL ACTIVITY OF C9-DEFICIENT HUMAN SERUM
AUTHOR: PRAMOONJAGO P; KINOSHITA T; HONG K; TAKATA-KOZONO Y; KOZONO H;
INAGI R; INOUE K
AUTHOR ADDRESS: DEP. BACTERIOL., OSAKA UNIV. MED. SCH., SUITA, OSAKA 565,
JAPAN.
JOURNAL: J IMMUNOL 148 (3). 1992. 837-843. 1992
FULL JOURNAL NAME: Journal of Immunology
CODEN: JOIMA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

9/3/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

05123429 EMBASE No: 1992263645
A monoclonal antibody (NMC-VIII/10) to factor VIII light chain
recognizing Glusup 1sup 6sup 7sup 5-Glusup 1sup 6sup 8sup 4 inhibits factor
VIII binding to endogenous von Willebrand factor in human umbilical vein
endothelial cells
Shima M.; Yoshioka A.; Nakajima M.; Nakai H.; Fukui H.
Department of Paediatrics, Nara Medical College, 840 Shijo-cho, Kashihara
City Japan
British Journal of Haematology (BR. J. HAEMATOL.) (United Kingdom)
1992, 81/4 (533-538)
CODEN: BJHEA ISSN: 0007-1048
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

9/3/5 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

07018562 93107207 PMID: 1281818
Influence of mitomycin C on endothelial monolayer regeneration in vitro.
Coomber BL
Department of Biomedical Sciences, Ontario Veterinary College, University
of Guelph, Canada.
Journal of cellular biochemistry (UNITED STATES) Nov 1992, 50
(3) p293-300, ISSN 0730-2312 Journal Code: HNF
Languages: ENGLISH
Document type: Journal Article
Record type: Completed

9/3/6 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06879246 92397717 PMID: 1523940
[Study of anti-idiotypic antibodies to human monoclonal antibody]
Harada R; Takahashi N; Owaki I; Kannagi R; Endo N; Morita N; Inoue M
Department of Clinical Science and Laboratory Medicine, School of
Medicine, Kyoto University, Japan.
Igaku kenkyu (JAPAN) Feb 1992, 62 (1) p1-18, ISSN 0076-597X
Journal Code: 0X4
Languages: JAPANESE
Document type: Journal Article
Record type: Completed

? ds

Set	Items	Description
S1	167	AU="WANG YI"
S2	12	S1 AND C5
S3	11	RD S2 (unique items)
S4	0	5G1? ANC C5
S5	5	5G1? AND C5
S6	2	RD S5 (unique items)
S7	445	C5(10N)ANTIBOD?(20N) (INHIBIT? OR BLOCK? OR THERAP? OR TREA- T? OR SUPPRESS? OR PREVENT? OR ANTAGONI?)
S8	11	S7 AND PY=1992
S9	6	RD S8 (unique items)

? s s7 and complement

445 S7
245449 COMPLEMENT
S10 354 S7 AND COMPLEMENT
? s s10 and py=1992

354 S10
1828395 PY=1992
S11 6 S10 AND PY=1992
? rd s11

...completed examining records
S12 2 RD S11 (unique items)
? t s12/3/all

12/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08377954 BIOSIS NO.: 000094108458
FORMATION AND STRUCTURE OF THE C5B-7 COMPLEX OF THE LYTIC PATHWAY OF
COMPLEMENT
AUTHOR: DISCIPIO R G
AUTHOR ADDRESS: DEP. IMMUNOLOGY IMM18, RESEARCH INSTITUTE SCRIPPS CLINIC,
10666 N. TORREY PINES RD., LA JOLLA, CALIF. 92037.
JOURNAL: J BIOL CHEM 267 (24). 1992. 17087-17094. 1992
FULL JOURNAL NAME: Journal of Biological Chemistry
CODEN: JBCHA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

12/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08064092 BIOSIS NO.: 000093085540
BACTERICIDAL ACTIVITY OF C9-DEFICIENT HUMAN SERUM
AUTHOR: PRAMOONJAGO P; KINOSHITA T; HONG K; TAKATA-KOZONO Y; KOZONO H;
INAGI R; INOUE K
AUTHOR ADDRESS: DEP. BACTERIOL., OSAKA UNIV. MED. SCH., SUITA, OSAKA 565,
JAPAN.
JOURNAL: J IMMUNOL 148 (3). 1992. 837-843. 1992
FULL JOURNAL NAME: Journal of Immunology
CODEN: JOIMA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH
? s s10 and py=1993

354 S10
1866049 PY=1993
S13 3 S10 AND PY=1993
? rd s13

...completed examining records
S14 1 RD S13 (unique items)
? t s14/3/all

14/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09081756 BIOSIS NO.: 199497090126
Platelet activation and inhibition of malarial cytoadherence by the
anti-CD36 IgM monoclonal antibody NL07.
AUTHOR: Alessio Massimo; Greco Nicholas J; Primo Luca; Ghigo Dario; Bosia
Amalia; Tandon Narendra N; Ockenhouse Christian F; Jamieson G A; Malavasi
Fabio(a)
AUTHOR ADDRESS: (a)Lab. Biologia Cellular, Via Santena 19, I-10126 Torino**
Italy
JOURNAL: Blood 82 (12):p3637-3647 1993
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
? s s10 and py=1994

354 S10
1922064 PY=1994
S15 12 S10 AND PY=1994
? rd s15

...completed examining records
S16 5 RD S15 (unique items)
? t s16/3/all

16/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09641901 BIOSIS NO.: 199598096819
Activation of **Complement** and Kinin Systems After Thrombolytic Therapy
in Patients With Acute Myocardial Infarction.
AUTHOR: Agostoni Angelo(a); Gardinali Marco; Frangi Donatella; Cafaro
Cristina; Conciato Luisa; Sponzilli Carlo; Salvioni Alessandro; Cugno
Massimo; Cicardi Marco
AUTHOR ADDRESS: (a)Inst. Intern. Med., University Milan, via Pace 15, Milan
20122**Italy
JOURNAL: Circulation 90 (6):p2666-2670 1994
ISSN: 0009-7322
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09418461 BIOSIS NO.: 199497426831

C5b-9 increases albumin permeability of isolated glomeruli in vitro.
AUTHOR: Savin Virginia J(a); Johnson Richard J; Couser William G
AUTHOR ADDRESS: (a)Div. Nephrol., 4015 Sudler, Univ. Kansas Med. Cent.,
39th and Rainbow Blvd., Kansas City, KS 661**USA
JOURNAL: Kidney International 46 (2):p382-387 1994
ISSN: 0085-2538
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09215626 BIOSIS NO.: 199497223996
Tissue distribution of **complement** regulatory membrane proteins in
rats.
AUTHOR: Funabashi K; Okada N; Matsuo S; Yamamoto T; Morgan B P; Okada H(a)
AUTHOR ADDRESS: (a)Dep. Molecular Biol., Nagoya City Univ. Sch. Med.,
Mizuho-cho, Nagoya 467**Japan
JOURNAL: Immunology 81 (3):p444-451 1994
ISSN: 0019-2805
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09165279 BIOSIS NO.: 199497173649
Neutrophil elicitation in the reverse passive Arthus reaction:
Complement-dependent and -independent mast cell involvement.
AUTHOR: Ramos Bernard F; Zhang Yan; Jakschik Barbara A(a)
AUTHOR ADDRESS: (a)Dep. Mol. Biol. Pharmacol., Washington Univ. Sch. Med.,
660 S. Euclid St., St. Louis, MO 63110**USA
JOURNAL: Journal of Immunology 152 (3):p1380-1384 1994
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

06034560 EMBASE No: 1995064800
Activation of **complement** and kinin systems after thrombolytic
therapy in patients with acute myocardial infarction: A comparison between
streptokinase and recombinant tissue-type plasminogen activator
Agostoni A.; Gardinali M.; Frangi D.; Cafaro C.; Conciato L.; Sponzilli
C.; Salvioni A.; Cugno M.; Cicardi M.
Institute of Internal Medicine, University of Milan, via Pace 15, Milan
20122 Italy
Circulation (CIRCULATION) (United States) 1994, 90/6 (2666-2670)
CODEN: CIRCA ISSN: 0009-7322
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
? s s10 and py=1995

1971752 PY=1995
S17 23 S10 AND PY=1995
? rd s17

...completed examining records
S18 8 RD S17 (unique items)
? rd s18

...completed examining records
S19 8 RD S18 (unique items)
? t s19/3/all

19/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10225205 BIOSIS NO.: 199698680123
In vitro and in vivo inhibition of **complement** activity by a
single-chain Fv fragment recognizing human C5.
AUTHOR: Evans Mark J(a); Rollins Scott A; Wolff Dennis W; Rother Russell P;
Norin Allen J; Therrien Denise M; Grijalva Galo A; Mueller John P; Nye
Steven H; Squinto Stephen P; Wilkins James A
AUTHOR ADDRESS: (a)Dep. Molecular Dev., Alexion Pharmaceuticals, 25 Science
Park, New Haven, CT 06511**USA
JOURNAL: Molecular Immunology 32 (16):p1183-1195 1995
ISSN: 0161-5890
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

19/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10178456 BIOSIS NO.: 199698633374
Monoclonal **antibodies** directed against human C5 and C8
block complement-mediated damage of xenogeneic cells and
organs.
AUTHOR: Rollins Scott A(a); Matis Louis A; Springhorn Jeremy P; Setter Eva;
Wolff Dennis W
AUTHOR ADDRESS: (a)Dep. Immunol., Alexion Pharmaceutical Inc., 25 Science
Park, New Haven, CT 06511**USA
JOURNAL: Transplantation (Baltimore) 60 (11):p1284-1292 1995
ISSN: 0041-1337
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

19/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10178445 BIOSIS NO.: 199698633363
Complement inhibition with an anti-C5 monoclonal
antibody prevents acute cardiac tissue injury in an ex vivo
model of pig-to-human xenotransplantation.
AUTHOR: Kroshus Timothy J(a); Rollins Scott A; Dalmaso Agustin P; Elliott
Eileen A; Matis Louis A; Squinto Stephen P; Bolman R Morton III
AUTHOR ADDRESS: (a)Dep. Surgery, Univ. Minn., Box 207, UMHC, 420 Delaware
St. SE, Minneapolis, MN 55455**USA
JOURNAL: Transplantation (Baltimore) 60 (11):p1194-1202 1995

ISSN: 0041-1337
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

19/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10155531 BIOSIS NO.: 199698610449
The membrane attack complex of **complement** mediates peripheral nervous system demyelination in vitro.
AUTHOR: Bruck W(a); Bruck Y; Diederich U; Piddlesden S J
AUTHOR ADDRESS: (a)Dep. Neuropathol., Univ. Goettingen, Robert-Koch-Strasse, D-37075 Goettingen**Germany
JOURNAL: Acta Neuropathologica 90 (6):p601-607 1995
ISSN: 0001-6322
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

19/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10081205 BIOSIS NO.: 199598536123
Anti-**C5** monoclonal **antibody therapy prevents** collagen-induced arthritis and ameliorates established disease.
AUTHOR: Wang Yi(a); Rollins Scott(a); Madri Joe; Matis Louis(a)
AUTHOR ADDRESS: (a)Alexion Pharmaceutical Inc., 25 Science Park, New Haven, CT 06511**USA
JOURNAL: Arthritis & Rheumatism 38 (9 SUPPL.):pS372 1995
CONFERENCE/MEETING: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals San Francisco, California, USA October 21-26, 1995
ISSN: 0004-3591
RECORD TYPE: Citation
LANGUAGE: English

19/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09847706 BIOSIS NO.: 199598302624
Monoclonal **antibodies to complement** component C5 in the **therapy** of inflammatory joint disease.
AUTHOR: Wang Y(a); Rollins S R(a); Madri J A; Elliott E A(a); Matis L A(a)
AUTHOR ADDRESS: (a)Alexion Pharm., New Haven, CT**USA
JOURNAL: Journal of Investigative Medicine 43 (SUPPL. 2):p362A 1995
CONFERENCE/MEETING: Clinical Research Meeting San Diego, California, USA May 5-8, 1995
RECORD TYPE: Citation
LANGUAGE: English

19/3/7 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

06221345 EMBASE No: 1995258401

Protection of retroviral vector particles in human blood through
complement inhibition

Rother R.P.; Squinto S.P.; Mason J.M.; Rollins S.A.

Alexion Pharmaceuticals, Inc., 25 Science Park, New Haven, CT 06511
United States

Human Gene Therapy (HUM. GENE THER.) (United States) 1995, 6/4
(429-435)

CODEN: HGTHE ISSN: 1043-0342

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

19/3/8 (Item 1 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

124127101 CA: 124(10)127101t PATENT

Anti-complement C5 antibodies for the treatment of glomerulonephritis and
other inflammatory diseases

INVENTOR(AUTHOR): Evans, Mark J.; Matis, Louis; Mueller, Eileen Elliott;
Nye, Steven H.; Rollins, Scott; Rother, Russell P.; Springhorn, Jeremy P.;
Squinto, Stephen P.; Thomas, Thomas C.; et al.

LOCATION: USA

ASSIGNEE: Alexion Pharmaceuticals, Inc.

PATENT: PCT International ; WO 9529697 A1 DATE: 951109

APPLICATION: WO 95US5688 (950501) *US 236208 (940502)

PAGES: 159 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/36A;
A61K-039/00B; A61K-039/395B; C07K-014/00B; C07K-014/75B; C07K-016/00B;
C07K-016/18B; C07K-016/36B; C07K-016/46B; C12N-005/10B; C12N-005/20B;
C12N-015/09B; C12N-015/10B; C12N-015/13B; C12N-015/63B; C12P-021/02B;
C12P-021/08B DESIGNATED COUNTRIES: AM; AU; BB; BG; BR; BY; CA; CN; CZ; EE;
FI; GE; HU; IS; JP; KG; KP; KR; KZ; LK; LR; LT; LV; MD; MG; MN; MX; NO; NZ;
PL; RO; RU; SG; SI; SK; TJ; TM; TT; UA; UG; US; UZ; VN

DESIGNATED REGIONAL: KE; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FR; GB;
GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE;
SN; TD; TG

?

2/3/101 (Item 37 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

02670678

Utility

METHODS FOR THE INHIBITION OF COMPLEMENT ACTIVATION

[Administering decorin to suppress antibody dependent complement activation
]

PATENT NO.: 5,650,389

ISSUED: July 22, 1997 (19970722)

INVENTOR(s): Krumdieck, Richard, Birmingham, AL (Alabama), US (United
States of America)
Hook, Magnus A. O., Houston, TX (Texas), US (United States of
America)
Volanakis, John E., Birmingham, AL (Alabama), US (United
States of America)

ASSIGNEE(s): University of Alabama at Birmingham Research Foundation, (A
U.S. Company or Corporation), Birmingham, AL (Alabama), US
(United States of America)
[Assignee Code(s): 24503]

APPL. NO.: 8-25,357

FILED: March 01, 1993 (19930301)

The government owns rights in the present invention pursuant to grant
numbers AI21067, AM27807, AR34614 from the National Institutes of Health.

FULL TEXT: 1715 lines

HODS FOR THE INHIBITION OF COMPLEMENT ACTIVATION

[Administering decorin to suppress antibody dependent complement activation
]

PATENT NO.: 5,650,389

ISSUED: July 22, 1997 (19970722)

INVENTOR(s): Krumdieck, Richard, Birmingham, AL (Alabama), US (United States of America)
Hook, Magnus A. O., Houston, TX (Texas), US (United States of America)
Volanakis, John E., Birmingham, AL (Alabama), US (United States of America)

ASSIGNEE(s): University of Alabama at Birmingham Research Foundation, (A U.S. Company or Corporation), Birmingham, AL (Alabama), US (United States of America)
[Assignee Code(s): 24503]

APPL. NO.: 8-25,357

FILED: March 01, 1993 (19930301)

The government owns rights in the present invention pursuant to grant numbers AI21067, AM27807, AR34614 from the National Institutes of Health.

FULL TEXT: 1715 lines
? t s2/kwic/101

2/KWIC/101 (Item 37 from file: 654)

DIALOG(R)File 654:(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

... J. A. Pitcock, and A. S. Townes. 1987. Passive transfer studies with type II collagen **antibody** in B10.D2/old and new line and C57B1/6 normal and beige (Chediak-Higashi) strains: Evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive **arthritis**. **Arthritis Rheum.** 30:460-465.

10. Lennon, V. A., M. E. Seybold, J. M. Lindstrom, C. Cochrane, and R. Ulevitch. 1978. Role of **complement** in the pathogenesis of experimental autoimmune myasthenia gravis. *J. Exp. Med.* 147:973-983.

11. Biesecker, G. and C. M. Gomez. 1989. **Inhibition** of acute passive transfer experimental autoimmune myasthenia gravis with Fab **antibody** to complement C6. *J. Immunol.* 142:2654-2659.

12. Salant, D. J., S. Belok, M...

2/3/5

DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 2002 Derwent Publ Ltd. All rts. reserv.

0176488 DBA Accession No.: 95-03309 PATENT
New synthetic peptide for human C5a receptor - **complement**-C5a
receptor monoclonal **antibody** for use as an antiinflammatory,
immunosuppressive or diagnostic agent
AUTHOR: Morgan E L; Ember J A; Hugli T E
PATENT ASSIGNEE: Scripps-Res.Inst. 1995
PATENT NUMBER: WO 9500164 PATENT DATE: 950105 WPI ACCESSION NO.:
95-051746 (9507)
PRIORITY APPLIC. NO.: US 79051 APPLIC. DATE: 930618
NATIONAL APPLIC. NO.: WO 94US6994 APPLIC. DATE: 940620
LANGUAGE: English

2/3/6

DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 2002 Derwent Publ Ltd. All rts. reserv.

0151149 DBA Accession No.: 93-09201 PATENT
Chimeric molecule comprising major histocompatibility complex and
immunoglobulin constant region - gene cloning, expression in CHO,
BW5147 or Sp2/0 cell culture and fusion protein cleavage with Factor-Xa
or collagenase for use in autoimmune disease therapy
PATENT ASSIGNEE: Anergen 1993
PATENT NUMBER: WO 9310220 PATENT DATE: 930527 WPI ACCESSION NO.:
93-182537 (9322)
PRIORITY APPLIC. NO.: US 795897 APPLIC. DATE: 911119
NATIONAL APPLIC. NO.: WO 92US10030 APPLIC. DATE: 921118
LANGUAGE: English

2/3/7

DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 2002 Derwent Publ Ltd. All rts. reserv.

0099156 DBA Accession No.: 90-01847 PATENT
Mutational analysis for mapping protein epitopes - new peptide interfering
with HIV virus infection of cells; application in AIDS therapy
PATENT ASSIGNEE: Gen.Hosp.Boston 1989
PATENT NUMBER: EP 341444 PATENT DATE: 891115 WPI ACCESSION NO.: 89-333831
(8946)
PRIORITY APPLIC. NO.: US 181826 APPLIC. DATE: 880415
NATIONAL APPLIC. NO.: EP 89106627 APPLIC. DATE: 890413
LANGUAGE: English

2/3/8

DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 2002 Derwent Publ Ltd. All rts. reserv.

0092209 DBA Accession No.: 89-10200 PATENT
Anti-type 3 **complement** receptor specific monoclonal **antibody** or
chimeric antibody - for use in the inhibition of recruitment of
myelomonocytic cells to inflammatory stimuli
PATENT ASSIGNEE: Rosen H 1989
PATENT NUMBER: WO 8904174 PATENT DATE: 890518 WPI ACCESSION NO.:
89-165510 (8922)
PRIORITY APPLIC. NO.: GB 8726230 APPLIC. DATE: 871110
NATIONAL APPLIC. NO.: WO 88GB977 APPLIC. DATE: 881110
LANGUAGE: English

? 4t s2/kwic/5-8

>>>Unrecognizable Command

? t s2/kwic/5-8

2/KWIC/5

DIALOG(R)File 357:(c) 2002 Derwent Publ Ltd. All rts. reserv.

- **complement**-C5a receptor monoclonal **antibody** for use as an antiinflammatory, immunosuppressive or diagnostic agent
...ABSTRACT: Gram-negative bacterium sepsis, acute respiratory distress syndrome, ischemic heart disease, post-dialysis syndrome, rheumatoid **arthritis**, AIDS and vasculitis, or as diagnostic agents. (67pp)
DESCRIPTORS: human recombinant **complement**-C5a receptor fragment prep., monoclonal **antibody** prep., hybridoma, anti-idiotypic antibody prep., appl. antiinflammatory, immunosuppressive, diagnostic mammal animal protein sequence cell...

2/KWIC/6

DIALOG(R)File 357:(c) 2002 Derwent Publ Ltd. All rts. reserv.

...ABSTRACT: constant region may contain an IgG1 hinge region, CH2 domain and CH3 domain, and fixes **complement** or mediates **antibody**-dependent cytotoxicity. A DNA cassette containing a cDNA encoding an Ig constant region C-gamma...
... MHC protein. The fusion protein is useful in therapy of autoimmune disease, e.g. rheumatoid **arthritis** or multiple sclerosis. (40pp)
DESCRIPTORS: ...gene cloning expression gene transmission enzyme blood-clotting protease EC-3.4.24.3 rheumatoid **arthritis** multiple sclerosis mammal

2/KWIC/7

DIALOG(R)File 357:(c) 2002 Derwent Publ Ltd. All rts. reserv.

...ABSTRACT: mutagenized forms of the gene of interest; (b) treating transfected cells with anti-E1 monoclonal **antibody** (mAb) in the presence of **complement** to lyse cells expressing E1; (c) treating non-lyzed cells with a mAb directed against...
DESCRIPTORS: ...new peptide for prevention of HIV virus binding to CD4 antigen, appl. in AIDS, asthma, **arthritis** therapy, transplant rejection cloning mammal cell culture monkey kidney gene transmission vector plasmid piH3MCD2 plasmid...

2/KWIC/8

DIALOG(R)File 357:(c) 2002 Derwent Publ Ltd. All rts. reserv.

Anti-type 3 **complement** receptor specific monoclonal **antibody** or chimeric antibody

ABSTRACT: An anti-type 3 **complement** receptor (anti-CR3) specific **antibody** (A) for use in the inhibition of recruitment of myelomonocytic acids to inflammatory stimuli is...

... antibodies are used for treatment of inflammatory, acute hypersensitivity and autoimmune diseases, e.g. rheumatoid **arthritis**, etc. (52pp)

DESCRIPTORS: **complement**-C3 receptor monoclonal **antibody** prep., chimeric antibody prep., humanized antibody prep., appl. to inflammatory, acute hypersensitivity, autoimmune disease, therapy...

?

nistering decorin to suppress antibody dependent complement activation
]

PATENT NO.: 5,650,389

ISSUED: July 22, 1997 (19970722)

INVENTOR(s): Krumdieck, Richard, Birmingham, AL (Alabama), US (United States of America)
Hook, Magnus A. O., Houston, TX (Texas), US (United States of America)
Volanakis, John E., Birmingham, AL (Alabama), US (United States of America)

ASSIGNEE(s): University of Alabama at Birmingham Research Foundation, (A U.S. Company or Corporation), Birmingham, AL (Alabama), US (United States of America)
[Assignee Code(s): 24503]

APPL. NO.: 8-25,357

FILED: March 01, 1993 (19930301)

The government owns rights in the present invention pursuant to grant numbers AI21067, AM27807, AR34614 from the National Institutes of Health.

METHODS OF TREATING TNF-.ALPHA.-MEDIATED CROHN'S DISEASE USING CHIMERIC ANTI-TNF ANTIBODIES

[Human tumor necrosis factor antibodies]

PATENT NO.: 5,656,272

ISSUED: August 12, 1997 (19970812)

INVENTOR(s): Le, Junming, Jackson Heights, NY (New York), US (United States of America)

Vilcek, Jan, New York, NY (New York), US (United States of America)

Dadonna, Peter, Palo Alto, CA (California), US (United States of America)

Ghrayeb, John, Thorndale, PA (Pennsylvania), US (United States of America)

Knight, David, Berwyn, PA (Pennsylvania), US (United States of America)

Siegel, Scott A., Westborough, MA (Massachusetts), US (United States of America)

ASSIGNEE(s): Centocor, Inc, (A U.S. Company or Corporation), Malvern, PA (Pennsylvania), US (United States of America)

New York University Medical Center, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)

[Assignee Code(s): 12273; 35102]

EXTRA INFO: Assignment transaction [Reassigned], recorded December 28, 1998 (19981228)

APPL. NO.: 8-192,102

FILED: February 04, 1994 (19940204)

2/3/60 (Item 3 from file: 653)
DIALOG(R)File 653:US Pat.Fulltext
(c) format only 2002 The Dialog Corp. All rts. reserv.

01623617

Utility

METHOD OF TREATING AUTOIMMUNE DISEASES THAT ARE MEDIATED BY LEU3/CD4
PHENOTYPE T CELLS

PATENT NO.: 4,695,459

ISSUED: September 22, 1987 (19870922)

INVENTOR(s): Steinman, Lawrence, Palo Alto, CA (California), US (United
States of America)
Waldor, Matthew K., Palo Alto, CA (California), US (United
States of America)
Sriram, Subramanian, Burlington, VT (Vermont), US (United
States of America)
Herzenberg, Leonard A., Stanford, CA (California), US (United
States of America)
Herzenberg, Leonore A., Stanford, CA (California), US (United
States of America)

ASSIGNEE(s): The Board of Trustees of Leland Stanford Junior University, (A
U.S. Company or Corporation), Stanford, CA (California), US
(United States of America)
[Assignee Code(s): 49136]

APPL. NO.: 6-686,126

FILED: December 26, 1984 (19841226)

2/3/59 (Item 2 from file: 653)
DIALOG(R)File 653:US Pat.Fulltext
(c) format only 2002 The Dialog Corp. All rts. reserv.

01633109

Utility

METHODS AND MATERIALS FOR TREATMENT OF RHEUMATOID ARTHRITIS
[IMMUNOGLOBULIN G PROVOCATIVE OF PHEUMATOID FACTOR FORMATION]

PATENT NO.: 4,704,273

ISSUED: November 03, 1987 (19871103)

INVENTOR(s): McMichael, John, P.O. Box 81, Cambridge Springs, PA
(Pennsylvania), US (United States of America), 16403
[Assignee Code(s): 68000]

EXTRA INFO: Assignment transaction [Reassigned], recorded July 31,
1989 (19890731)

Expired, effective November 3, 1999 (19991103), recorded in
O.G. of January 11, 2000 (20000111)

APPL. NO.: 6-833,998

FILED: February 27, 1986 (19860227)

Continuation-in-part of serial number 6-708,274 filed March 05, 1985 now
pending which is a division of serial number 6-378,752 filed May 17, 1982
now patent 4,521,405.

FULL TEXT: 858 lines

2/KWIC/101 (Item 37 from file: 654)
DIALOG(R)File 654:(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

... J. A. Pitcock, and A. S. Townes. 1987. Passive transfer studies with type II collagen **antibody** in B10.D2/old and new line and C57B1/6 normal and beige (Chediak- Higashi) strains: Evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive **arthritis**. **Arthritis Rheum.** 30:460-465.

10. Lennon, V. A., M. E. Seybold, J. M. Lindstrom, C. Cochrane, and R. Ulevitch. 1978. Role of **complement** in the pathogenesis of experimental autoimmune myasthenia gravis. *J. Exp. Med.* 147:973-983.

11. Biesecker, G. and C. M. Gomez. 1989. **Inhibition** of acute passive transfer experimental autoimmune myasthenia gravis with Fab **antibody** to complement C6. *J. Immunol.* 142:2654-2659.

12. Salant, D. J., S. Belok, M...

s 5G1(w)1 and antibod? and c5

19 5G1
7549845 1
5 5G1(W)1
1595708 ANTIBOD?
19920 C5
S9 4 5G1(W)1 AND ANTIBOD? AND C5
? ds

Set	Items	Description
S1	44	E3,E4
S2	17	S1 AND C5
S3	16	RD S2 (unique items)
S4	382	C5 AND (ARTHRITIS)
S5	977	(ANTIBOD\$ OR ANTAGONIS? OR INHIBITOR?) (20N) (COMPLEMENT OR - C5) AND (TREAT? OR THERAP? OR PREVENT? OR BLOCK? OR INHIBIT? - OR SUPPRESS?) (20N) (ARTHRITIS OR INFLAMM? OR AUTOIMMUN?)
S6	91	S5 AND C5
S7	63	RD S6 (unique items)
S8	0	5G1(W)1 AND ANTIBOD? AND C5
S9	4	5G1(W)1 AND ANTIBOD? AND C5

? rd s9

...completed examining records
S10 1 RD S9 (unique items)
? t s10/3/all

10/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

10974348 BIOSIS NO.: 199799595493
Inhibition of complement activity by humanized anti-C5 antibody
and single-chain Fv.
AUTHOR: Thomas Thomas C(a); Rollins Scott A; Rother Russell P; Giannoni
Michelle A; Hartman Sandra L; Elliott Eileen A; Nye Steven H; Matis Louis
A; Squinto Stephen P; Evans Mark J
AUTHOR ADDRESS: (a)Alexion Pharmaceuticals, 25 Science Park, New Haven, CT
06511**USA
JOURNAL: Molecular Immunology 33 (17-18):p1389-1401
ISSN: 0161-5890
RECORD TYPE: Abstract
LANGUAGE: English

08748607 96323263

Amelioration of lupus-like **autoimmune** disease in NZB/WF1 mice after **treatment** with a **blocking** monoclonal antibody specific for complement component **C5**.

Wang Y; Hu Q; Madri JA; Rollins SA; Chodera A; Matis LA
Immunobiology Program, Alexion Pharmaceuticals, Inc., New Haven, CT 06511, USA.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 6 1996, 93 (16) p8563-8, ISSN 0027-8424
Journal Code: PV3

Languages: ENGLISH

Document type: JOURNAL ARTICLE

New Zealand black x New Zealand white (NZB/W) F1 mice spontaneously develop an autoimmune syndrome with notable similarities to human systemic lupus erythematosus. Female NZB/WF1 mice produce high titers of antinuclear antibodies and invariably succumb to severe glomerulonephritis by 12 months of age. Although the development of the immune-complex nephritis is accompanied by abundant local and systemic complement activation, the role of proinflammatory complement components in disease progression has not been established. In this study we have examined the contribution of activated terminal complement proteins to the pathogenesis of the lupus-like **autoimmune** disease. Female NZB/W F1 mice were **treated** with a monoclonal antibody (mAb) specific for the **C5** component of complement that blocks the cleavage of **C5** and thus prevents the generation of the potent proinflammatory factors C5a and C5b-9. Continuous therapy with anti-**C5** mAb for 6 months resulted in significant amelioration of the course of glomerulonephritis and in markedly increased survival. These findings demonstrate an important role for the terminal complement cascade in the progression of renal disease in NZB/W F1 mice, and suggest that mAb-mediated **C5** inhibition may be a useful approach to the therapy of immune-complex glomerulonephritis in humans.

7/7/31 (Item 13 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

06082672 EMBASE No: 1995113159

Complement in organ transplantation: Contributions to inflammation,
injury, and rejection

Baldwin III W.M.; Pruitt S.K.; Brauer R.B.; Daha M.R.; Sanfilippo F.
Department of Pathology, Ross Research Building, Johns Hopkins
University, 720 Rutland Ave., Baltimore, MD 21205-2196 United States
Transplantation (TRANSPLANTATION) (United States) 1995, 59/6 (797-808)
CODEN: TRPLA ISSN: 0041-1337
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Caren and Rosenberg (149) alluded to the difficulties inherent in studying the effects of complement on graft rejection in 1965: 'The role of 'complement' in immunologic reactions is known with considerable uncertainty. Experiments designed to test the importance of complement are beset with the hazards attendant upon study of complex reactions of ill-defined largely uncharacterized proteins in biologic systems.' Since then the structure and function of the components and regulatory molecules of the complement cascade have been well characterized. As a result of these advances it has become apparent that many aspects of acute and chronic rejection can be affected by complement because split products of complement influence the localization, activation, and effector functions of platelets, granulocytes, monocytes, and lymphocytes. Because most immunosuppressive protocols have been directed at inhibiting cellular immunity, **complement**-mediated graft injury may be accentuated in the clinical setting. **Complement inhibitors**, such as recombinant human sCR1, have already been found to delay effectively hyperacute rejection in rats and in preclinical primate trails. If these agents also prove effective in delaying acute rejection, they could have clinical application in rejection episodes that are associated with complement activation.

06253847 EMBASE No: 1995280611

Anti-C5 monoclonal antibody **therapy prevents**
collagen-induced **arthritis** and ameliorates established disease

Wang Y.; Rollins S.A.; Madri J.A.; Matis L.A.

Immunobiology Program, Alexion Pharmaceuticals, Inc., New Haven, CT 06511
United States

Proceedings of the National Academy of Sciences of the United States of
America (PROC. NATL. ACAD. SCI. U. S. A.) (United States) 1995, 92/19
(8955-8959)

CODEN: PNASA ISSN: 0027-8424

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Activated components of the complement system are potent mediators of inflammation that may play an important role in numerous disease states. For example, they have been implicated in the pathogenesis of inflammatory joint diseases including rheumatoid **arthritis** (RA). To target complement activation in immune-mediated joint **inflammation**, we have utilized monoclonal antibodies (mAbs) that **inhibit** the complement cascade at **C5**, **blocking** the generation of the major chemotactic and proinflammatory factors C5a and C5b-9. In this study, we demonstrate the efficacy of a mAb specific for murine **C5** in the **treatment** of collagen-induced **arthritis**, an animal model for RA. We show that systemic administration of the anti-C5 mAb effectively **inhibits** terminal complement activation in vivo and **prevents** the onset of **arthritis** in immunized animals. Most important, anti-C5 mAb **treatment** is also highly effective in ameliorating established disease. These results demonstrate a critical role for activated terminal complement components not only in the induction but also in the progression of collagen-induced **arthritis** and suggest that **C5** may be an attractive **therapeutic** target in RA.

07186393 EMBASE No: 1998074805

Novel **complement inhibitors**

Liszewski M.K.; Atkinson J.P.

M.K. Liszewski, Division of Rheumatology, Department of Medicine,
Washington University, 660 South Euclid, St Louis, MO 63110 United
States

Expert Opinion on Investigational Drugs (EXPERT OPIN. INVEST. DRUGS) (United Kingdom) 1998, 7/3 (323-332)

CODEN: EOIDE ISSN: 1354-3784

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 32

The complement system provides natural immunity against microbes and is an effector arm of antibody-mediated humoral immunity. It promotes the inflammatory process by activating cells and facilitates microbial destruction through opsonisation and lysis. Given this tissue damaging potential, it is not surprising that nearly half of the proteins of the complement system are regulators. The complement system can mediate undesirable cellular damage in autoantibody-mediated conditions, for example myasthenia gravis, immune-complex excess syndromes, such as systemic lupus erythematosis, ischaemia-reperfusion states, hyperacute rejection of transplants, organ failure conditions (e.g., adult respiratory distress syndrome (ARDS)), Alzheimer's disease (AD) and related neurodegenerative disorders. A **complement inhibitor** has been lacking in the therapeutic arsenal. However, there are now several such agents being assessed in clinical trials and others under development. Current approaches include soluble versions of membrane regulatory proteins, humanised antibodies to components, small molecule **inhibitors** at various stages of the pathway and transgenic animals expressing human **complement** regulators for xenotransplantation. These and other strategies should lead to an effective means with which to inhibit complement activation in clinical medicine.

07310970 BIOSIS NO.: 000090090863

SOLUBLE HUMAN **COMPLEMENT** RECEPTOR TYPE 1 IN-VIVO **INHIBITOR** OF
COMPLEMENT SUPPRESSING POST-ISCHEMIC MYOCARDIAL
INFLAMMATION AND NECROSIS

AUTHOR: WEISMAN H F; BARTOW T; LEPPA M K; MARSH H C JR; CARSON G R; CONCINO
M F; BOYLE M P; ROUX K H; WEISFELDT M L; FEARON D T

AUTHOR ADDRESS: DEP. MED., JOHNS HOPKINS UNIV. SCH. MED., BALTIMORE, MD.
21205.

JOURNAL: SCIENCE (WASHINGTON D C) 249 (4965). 1990. 146-151. 1990

FULL JOURNAL NAME: SCIENCE (Washington D C)

CODEN: SCIEA

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: The **complement** system is an important mediator of the acute
inflammatory response, and an effective **inhibitor** would
suppress tissue damage in many **autoimmune** and
inflammatory diseases. Such an **inhibitor** might be found among
the endogenous regulatory proteins of **complement** that **block**
the enzymes that activate C3 and C5. Of these proteins,
complement receptor type 1 (Cr1; CD35) has the most
inhibitory potential, but its restriction to a few cell types
limits its function in vivo. This limitation was overcome by the
recombinant, soluble human CR1, sCR1, which lacks the transmembrane and
cytoplasmic domains. The sCR1 bivalently bound dimeric forms of its
ligands, C3b and methylamine-treated C4 (C4-ma), and promoted their
inactivation by factor I. In nanomolar concentrations, sCR1 **blocked**
complement activation in human serum by the two pathways. The sCR1
had **complement inhibitory** and anti-**inflammatory**
activities in a rat model of reperfusion injury of ischemic myocardium,
reducing myocardial infarction size by 44 percent. These findings
identify sCR1 as a potential agent for the **suppression** of
complement-dependent tissue injury in **autoimmune** and
inflammatory diseases.

BIOSIS. All rts. reserv.

07953687 BIOSIS NO.: 000093032785

THE **INHIBITORY** EFFECT OF ROSMARINIC ACID ON **COMPLEMENT** INVOLVES
THE **C5** CONVERTASE

AUTHOR: PEAKE P W; PUSSELL B A; MARTYN P; TIMMERMANS V; CHARLESWORTH J A
AUTHOR ADDRESS: RENAL LABORATORY, DEP. NEPHROLOGY, PRINCE HENRY HOSPITAL,
UNIVERSITY NEW SOUTH WALES, SYDNEY, NSW, AUST.

JOURNAL: INT J IMMUNOPHARMACOL 13 (7). 1991. 853-858. 1991

FULL JOURNAL NAME: International Journal of Immunopharmacology

CODEN: IJIMD

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: Rosmarinic acid (RA), a naturally occurring extract from *Melissa officinalis*, **inhibits** several complement-dependent **inflammatory** processes and may have potential as a **therapeutic** agent for the control of complement activation in disease. Rosmarinic acid has been reported to have effects on both the classical pathway C3-convertase and on the cobra venom factor-induced, alternative pathway convertase. In order to define the mechanism of inhibition, the effect of RA on classical and alternative pathway lysis, Clq binding, the classical pathway convertase, the alternative pathway convertase, membrane attack pathway lysis and the generation of fragments of C3 and **C5** during activation, was tested in vitro. The results showed that RA inhibited lysis by the classical pathway more than by the alternative pathway. This effect was dose-dependent with maximum inhibition of classical pathway lysis observed at 2.6 mmoles of RA. There was little effect on Clq binding or on the classical and alternative pathway convertases. However, there was highly significant inhibition of lysis of pre-formed EA43b cells by dilutions of human or rabbit serum in the presence of RA (1 mM); this was accompanied by inhibition of C5a generation. We conclude that the **inhibitory** effect of RA involves the **C5** convertase. Such inhibition could be advantageous to the host in disorders where the terminal attack sequence plays a role in pathogenesis.

348 BIOSIS NO.: 199799595493

Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

AUTHOR: Thomas Thomas C(a); Rollins Scott A; Rother Russell P; Giannoni Michelle A; Hartman Sandra L; Elliott Eileen A; Nye Steven H; Matis Louis A; Squinto Stephen P; Evans Mark J

AUTHOR ADDRESS: (a)Alexion Pharmaceuticals, 25 Science Park, New Haven, CT 06511**USA

JOURNAL: Molecular Immunology 33 (17-18):p1389-1401

ISSN: 0161-5890

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Activation of the complement system contributes significantly to the pathogenesis of numerous acute and chronic diseases. Recently, a monoclonal antibody (5G1.1) that recognizes the human complement protein C5, has been shown to effectively **block** C5 cleavage, thereby **preventing** the generation of the pro-inflammatory complement components C5a and C5b-9. Humanized 5G1.1 antibody, Fab and scFv molecules have been produced by grafting the complementarity determining regions of 5G1.1 on to human framework regions. Competitive ELISA analysis indicated that no framework changes were required in the humanized variable regions for retention of high affinity binding to C5, even at framework positions predicted by computer modeling to influence CDR canonical structure. The humanized Fab and scFv molecules blocked complement-mediated lysis of chicken erythrocytes and porcine aortic endothelial cells in a dose-dependent fashion, with complete complement inhibition occurring at a three-fold molar excess, relative to the human C5 concentration. In contrast to a previously characterized anti-C5 scFv molecule, the humanized h5G1.1 scFv also effectively blocked C5a generation. Finally, an intact humanized h5G1.1 antibody blocked human complement lytic activity at concentrations identical to the original murine monoclonal antibody. These results demonstrate that humanized h5G1.1 and its recombinant derivatives retain both the affinity and blocking functions of the murine 5G1.1 antibody, and suggest that these molecules may serve as potent **inhibitors** of complement-mediated pathology in human **inflammatory** diseases.

7/7/7 (Item 7 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

09488209 BIOSIS NO.: 199497496579

Mapping of the C5a receptor signal transduction network in human neutrophils.

AUTHOR: Buhl Anne Mette(a); Avdi Natalie; Worthen G Scott; Johnson Gary L
AUTHOR ADDRESS: (a)Div. Biostructural Chem., Dep. Chem., University Aarhus, DK-8000 Aarhus**Denmark

JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 91 (19):p9190-9194 1994

ISSN: 0027-8424

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Human neutrophils respond to chemoattractants, resulting in their accumulation at an **inflammatory** site. Chemoattractants such as the C5a peptide, derived from the C5 complement factor, bind to **inhibitory** guanine nucleotide binding protein (G-i)-coupled seven

membrane-spanning receptors expressed in neutrophils. C5a receptor activation results in the G-i-dependent activation of the mitogen-activated protein (MAP) kinase pathway in human neutrophils. C5a receptor ligation activates both B-Raf and Raf-1, with B-Raf activation overlapping but temporally distinct from that of Raf-1. B-Raf and Raf-1 both efficiently phosphorylate MAP kinase kinase (MEK-1). C5a also stimulates guanine nucleotide exchange and activation of Ras. Ras and Raf activation in response to C5a involves protein kinase C-dependent and -independent pathways. Activation of both Raf-1 and B-Raf was inhibited by protein kinase A stimulation, consistent with the inhibitory effects of increased cAMP levels on neutrophil function. The findings define a functional signal transduction pathway linking the neutrophil C5a chemoattractant receptor to the regulation of Ras, B-Raf, Raf-1, and MAP

7/7/5 (Item 5 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11340383 BIOSIS NO.: 199800121715
Controlling the complement system in inflammation.
AUTHOR: Kirschfink Michael(a)
AUTHOR ADDRESS: (a)Inst. Immunol., Univ. Heidelberg, Im Neuenheimer Feld
305, 69120 Heidelberg**Germany
JOURNAL: Immunopharmacology 38 (1-2):p51-62 Dec., 1997
ISSN: 0162-3109
DOCUMENT TYPE: Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Inappropriate or excessive activation of the complement system can lead to harmful, potentially life-threatening consequences due to severe inflammatory tissue destruction. These consequences are clinically manifested in various disorders, including septic shock, multiple organ failure and hyperacute graft rejection. Genetic complement deficiencies or complement depletion have been proven to be beneficial in reducing tissue injury in a number of animal models of severe complement-dependent **inflammation**. It is therefore believed that **therapeutic inhibition** of complement is likely to arrest the process of certain diseases. Attempts to efficiently inhibit **complement** include the application of endogenous soluble **complement inhibitors** (C1-inhibitor, recombinant soluble **complement** receptor 1-rsCR1), the administration of antibodies, either blocking key proteins of the cascade reaction (e.g. C3, C5), neutralizing the action of the complement-derived anaphylatoxin C5a, or interfering with complement receptor 3 (CR3, CD 18/11b)-mediated adhesion of inflammatory cells to the vascular endothelium. In addition, incorporation of membrane-bound complement regulators (DAF-CD55, MCP-CD46, CD59) has become possible by transfection of the correspondent cDNA into xenogeneic cells. Thereby, protection against complement-mediated inflammatory tissue damage could be achieved in various animal models of sepsis, myocardial as well as intestinal ischemia/reperfusion injury, adult respiratory distress syndrome, nephritis and graft rejection. Supported by results from first clinical trials, **complement inhibition** appears to be a suitable **therapeutic** approach to control **inflammation**. Current strategies to specifically **inhibit** complement in **inflammation** have been discussed at a recent meeting on the 'Immune Consequences of Trauma, Shock and Sepsis', held from March 4-8, 1997, in Munich, Germany. The Congress (chairman: E. Faist, Munich, Germany), which was held in close cooperation with various national and international shock and trauma societies, was attended by about 2000 delegates from 40 countries. The major objective of the meeting was to provide an overview on the most state-of-the-art methods to **prevent** multiple organ dysfunction syndrome (MODS)/multiple organ failure (MOF) following the systemic **inflammatory** response (SIRS) to severe trauma. One of the largest symposia held within the Congress was devoted to current aspects of controlling complement in inflammation (for abstracts see: Shock 1997, 7 Suppl., 71-75). After providing the audience with information on the scientific background by addressing the clinical relevance of complement activation (G.O. Till, Ann Arbor, MI, USA) and discussing recent developments in modern complement diagnosis (J. Kohl, Hannover, Germany), B.P. Morgan (Cardiff, UK) introduced the symposium's special issue by giving an overview on **complement** regulatory molecules. Selected topics included overviews on the application of C1 **inhibitor** (C.E.

Hack, Amsterdam, NL), sCRI (U.S. Ryan, Needham, MA, USA), antibodies to C5 (Y. Wang, New Haven, CT, USA) and to the anaphylatoxin C5a (M. Oppermann, Gottingen, Germany), and a report on complement **inhibition** in cardiopulmonary bypass (T.E. Mollnes, Bodo, Norway). The growing interest of clinicians in complement-directed anti-**inflammatory therapy**, and the fact that only some of the various aspects of **therapeutic complement inhibition** could be addressed on the meeting, has motivated the author to expand a Congress report into a short comprehensive review on recent strategies to control complement in inflammation.

7/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12324047 BIOSIS NO.: 200000077549

Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody **C5 complement inhibitor** in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.

AUTHOR: Fitch Jane CK(a); Rollins Scott; Matis Louis; Alford Bernadette; Aranki Sary; Collard Charles D; Dewar Michael; Elefteriades John; Hines Roberta; Kopf Gary; Kraker Philip; Li Lan; O'Hara Ruth; Rinder Christine; Rinder Henry; Shaw Richard; Smith Brian; Stahl Gregory; Shernan Stanton K

AUTHOR ADDRESS: (a)Department of Anesthesiology, Baylor College of Medicine, 6550 Fannin, Suite 1003, Houston, TX**USA

JOURNAL: Circulation 100 (25):p2499-2506 Dec. 21-28, 1999

ISSN: 0009-7322

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: Background-Cardiopulmonary bypass (CPB) induces a systemic inflammatory response that causes substantial clinical morbidity. Activation of **complement** during CPB contributes significantly to this **inflammatory** process. We examined the capability of a novel **therapeutic complement inhibitor** to prevent pathological **complement** activation and tissue injury in patients undergoing CPB. Methods and Results-A humanized, recombinant, single-chain antibody specific for human **C5**, h5G1.1-scFv, was intravenously administered in 1 of 4 doses ranging from 0.2 to 2.0 mg/kg before CPB. h5G1.1-scFv was found to be safe and well tolerated. Pharmacokinetic analysis revealed a sustained half-life from 7.0 to 14.5 hours. Pharmacodynamic analysis demonstrated significant dose-dependent inhibition of complement hemolytic activity for up to 14 hours at 2 mg/kg. The generation of proinflammatory complement byproducts (sC5b-9) was effectively inhibited in a dose-dependent fashion. Leukocyte activation, as measured by surface expression of CD11b, was reduced ($P<0.05$) in patients who received 1 and 2 mg/kg. There was a 40% reduction in myocardial injury (creatinine kinase-MB release, $P=0.05$) in patients who received 2 mg/kg. Sequential Mini-Mental State Examinations (MMSE) demonstrated an 80% reduction in new cognitive deficits ($P<0.05$) in patients treated with 2 mg/kg. Finally, there was a 1-U reduction in postoperative blood loss ($P<0.05$) in patients who received 1 or 2 mg/kg. Conclusions-A single-chain antibody specific for human **C5** is a safe and effective **inhibitor** of pathological **complement** activation in patients undergoing CPB. In addition to significantly reducing sC5b-9 formation and leukocyte CD11b expression, **C5** inhibition significantly attenuates postoperative myocardial injury, cognitive deficits, and blood loss. These data suggest that **C5 inhibition** may represent a novel **therapeutic** strategy for **preventing** complement-mediated **inflammation** and tissue injury.